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1. Summary 
The prognosis of glioblastoma, the most common type of intrinsic brain tumor, 
remains poor even with the current standard of care of the combination of surgery, 
radiotherapy, and chemotherapy. Multiple target inhibition has gained considerable 
interest in combating drug resistance in glioblastoma. However, understanding the 
molecular mechanisms of crosstalk between signaling pathways and predicting 
responses of cancer cells to targeted interventions has remained challenging.  
Among the multiple signaling pathways associated with glioblastoma, the 
hepatocyte growth factor (HGF)/c-MET and transforming growth factor (TGF)-β 
pathways have gained particular attention because of their putative roles in 
glioblastoma stem cell function, in the development of invasiveness and resistance 
to radio- and chemo-therapy as well as targeted therapies. Despite the significant 
role attributed to HGF/c-MET and TGF-β signaling in glioblastoma pathogenesis, 
their functional interactions have not been well characterized. In this thesis, using 
genetic and pharmacological approaches to stimulate or antagonize the TGF-β-
pathway in human glioma-initiating cells (GIC), we observed that TGF-β exerts an 
inhibitory effect on HGF/c-MET signaling, which is mediated by mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK). Moreover, TGF-
β control of HGF/c-MET is also regulated by phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B (PKB/AKT) pathway. A comparison of c-MET-driven and c-
MET independent GIC models revealed that TGF-β inhibits stemness in GIC at least 
in part via its negative regulation of c-MET activity, suggesting that the balance 
between these two oncogenic pathways may control stem cell maintenance. 
Importantly, immunohistochemical analyses of TGF-β and p-c-MET in human 
glioblastoma specimens support a concept of negative regulation between these 
pathways. 
These novel insights into the crosstalk of two major pathogenic pathways in 
glioblastoma may explain some of the disappointing results when targeting either 
pathway alone in human glioblastoma patients and inform on potential future 
designs on targeted pharmacological or genetic intervention. 
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2. Zusammenfassung 
Die Prognose des Glioblastoms, des häufigsten Typs eines intrinsischen 
Hirntumors, bleibt auch bei dem derzeitigen Therapiestandard der Kombination von 
Chirurgie, Strahlentherapie und Chemotherapie schlecht. Zielgerichtete Therapien 
haben grosses Interesse auch bei der Űberwindung der Therapieresistenz beim 
Glioblastom hervorgerufen. Das Verständnis der molekularen Mechanismen der 
Interaktionen zwischen den verschiedenen Signalwegen und die Vorhersage der 
Reaktionen von Tumorzellen auf zielgerichtete Interventionen bleibt aber 
unvollständig. 
Unter den multiplen Signalwegen, die bei Glioblastomen verändert sind, haben die 
Signalwege des Hepatozyten-Wachstumsfaktors (HGF) und seines Rezeptors c-
MET und des Transformierenden Wachstumsfaktors (TGF)-β aufgrund ihrer 
vermeintlichen Rollen für Glioblastom-Stammzellen und die Entwicklung von 
Invasivität und Resistenz gegenüber Strahlen- und Chemotherapie besonderes 
Interesse hervorgerufen. Trotz der signifikanten Rolle, die diesen Wachstumsfaktor-
Signalwegen bei der Glioblastom-Pathogenese zugeschrieben wird, sind ihre 
funktionellen Interaktionen nicht gut charakterisiert. 
In dieser Arbeit wurde mit Hilfe genetischer und pharmakologischer Ansätze zur 
Stimulierung oder Antagonisierung des TGF-β-Signalweges in humanen Gliom-
initiierenden Zellen (GIC) nachgewiesen, dass TGF-β eine hemmende Wirkung auf 
die HGF/c-MET-Signaltransduktion ausübt, welche durch mitogen-aktivierte 
Proteinkinase (MAPK/ERK) vermittelt wird. Ebenfalls wird diese Regulierung des 
HGF/c-MET-Signalwegs durch TGF-β durch Phosphatidylinositol-3-Kinase 
(PI3K)/protein kinase B (PKB/AKT)-Signalwege kontrolliert. 
Desweiteren zeigte ein Vergleich von c-MET-abhängigen und c-MET-unabhängigen 
GIC-Modellen, dass TGF-β die Stammzelleigenschaften in GIC zumindest teilweise 
über die negative Regulierung der c-MET-Aktivität hemmt. Dies deutet darauf hin, 
dass der Stammzell-Pool durch das Gleichgewicht zwischen diesen beiden 
onkogenen Signalwegen kontrolliert wird. Die immunhistochemischen Analysen von 
TGF-β und phosphoryliertem c-MET in humanen Glioblastomschnitten unterstützen 
die Hypothese der negativen Regulation zwischen diesen Signalwegen. 
Diese neue Betrachtung der Interaktion zwischen zwei wichtigen pathogenen 
Signalwegen im Glioblastom können einige enttäuschende Ergebnisse erklären, 
 14 
 
wenn entweder TGF-β oder HGF/c-MET allein beim Glioblastom gehemmt wurde, 
und zeigt auf, wie zukünftige gezielte pharmakologische oder genetische 
Interventionen erfolgreicher verlaufen könnten. 
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3. Introduction 
3.1 Glioblastoma 
3.1.1 The 2016 World Health Organization classification of the gliomas  
Gliomas represent 80% of all malignant primary brain tumors and are responsible 
for the majority of brain tumor-related deaths (Weller et al., 2015). The 2016 WHO 
classification of tumors of the central nervous system (CNS) categorizes gliomas 
into distinct entities according to integrated histological and molecular criteria, which 
provides a more accurate and reproducible diagnostic system (Reifenberger et al., 
2016). Prior to the 2016 WHO classification, gliomas were solely grouped into four 
histopathological and prognostic grades (WHO grade I-IV). WHO grade I defines 
non-infiltrative, slow-growing lesions with favourable prognosis. WHO grade II 
indicates slow-growing but infiltrative tumors that usually recur and tend to progress 
to higher grades. WHO grade III lesions are characterized by nuclear atypia and 
high mitotic activity. WHO grade IV designation indicates the most malignant and 
incurable tumors (Louis et al., 2007). Grade II-IV tumors exhibit diffuse invasion into 
the surrounding tissue without demarcated margins. The main advance of the 2016 
WHO classification is the incorporation of isocitrate dehydrogenase 1 or 2 (IDH)-
mutations, nuclear expression of the alpha thalassemia/mental retardation 
syndrome X-linked (ATRX), short arm of chromosome 1 (1p)/long arm of 
chromosome 19 (19q) co-deletion and histone 3 lysine 27 to-methionine (H3-K27M)-
mutation as diagnostic biomarkers to define glioma subtypes. The revised 
classification of diffuse gliomas includes: IDH-mutant and 1p/19q-codeleted 
oligodendroglioma of WHO grade II-III, IDH-mutant diffuse astrocytoma of WHO 
grade II-III, IDH-wild-type glioblastoma of WHO grade IV, IDH-mutant glioblastoma 
of WHO grade IV, and H3-K27M-mutant diffuse midline glioma of WHO grade IV 
(Reifenberger et al., 2016) (Fig. 1).  
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Figure 1. Diagnostic approach for integrated histological and molecular classification 
of diffuse gliomas according to the 2016 WHO classification of tumors of the CNS. 
The integrated analysis of IDH-mutation status together with histologic feature define 
glioma subtypes. ‡ IDH-wild-type astrocytomas of WHO grade II or III are considered 
provisional entities. The presence of 1p/19q codeletion in IDH-mutant patients 
maintaining nuclear ATRX expression constitute additional parameters for tumor 
classification. Further, H3-K27M mutations can be assessed in IDH-wild-type tumors. 
Dashed lines indicate smaller subgroups of tumors with the respective diagnoses. 
*The majority of IDH-wild-type WHO grade II or III astrocytic tumors retain nuclear 
ATRX expression. IDH-wild-type WHO grade II or III astrocytomas are temporary 
entities in the 2016 WHO classification of tumors of the CNS. Adapted from 
(Reifenberger et al., 2016). 
 
 
3.1.2 Characteristics of glioblastoma 
Glioblastoma (WHO grade IV) accounts for the 45-50% of all gliomas, thus 
representing the most common primary malignant brain tumor. Its annual incidence 
in the United States (U.S.) is 3.2 new cases per 100 000 population. Several 
environmental factors have been analysed as a potential cause of glioblastoma 
development however ionizing radiation is the only accepted risk factor (Ostrom et 
al., 2015). The 2016 CNS WHO classification incorporated distinction between (1) 
IDH-wild-type glioblastoma (90%), frequently defined as primary glioblastoma, 
predominating in patients over 50 years of age and (2) IDH-mutant glioblastoma 
(10%) which frequently develops from lower grade gliomas (secondary 
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glioblastoma), commonly in younger patients. IDH-mutated glioblastoma is 
associated with longer clinical history (15 months) compared to the IDH-wild type (4 
months) (Louis et al., 2016). Although these two glioblastoma subtypes are 
histologically almost indistinguishable, they diverge at genetic and epigenetic level, 
with IDH-mutant glioblastomas displaying less necrosis and better prognosis 
(Ohgaki and Kleihues, 2013) (Table 1).  
 
 
Table 1. Key characteristics of IDH-wild-type and IDH-mutant glioblastomas (Louis et 
al., 2016). 
 
The lesions are frequently unilateral, however, those localized in the brain stem and 
corpus callosum can involve both hemispheres and the latter termed “butterfly 
glioblastoma”.  
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Histopathology parameters such as nuclear atypia, cellular pleomorphism, high 
mitotic activity, microvascular proliferation and necrosis delineate glioblastomas 
(Ohgaki and Kleihues, 2013) (Fig. 2A). Although a prominent proliferative activity, 
detected by KI-67 expression is associated with glioblastoma, a correlation between 
the proliferation index and the clinical outcome of glioblastoma patients has not been 
confirmed (Moskowitz et al., 2006). Glioblastomas infiltrate surrounding brain 
structures but metastasis is uncommon in patients without preceding surgical 
intervention. The anatomical localization and the tumor size define the clinical 
features of glioblastoma. Common symptoms include neurological disorders like 
hemiparesis and aphasia, behavioural and neurocognitive deficits. Magnetic 
resonance imaging (MRI) represents the conventional diagnostic tool for the 
examination of a patient with suspected or confirmed glioblastoma. Radiologically, 
glioblastomas appear as a ring-enhancing proliferative periphery zone around a 
non-enhancement necrotic centre (Nakada et al., 2011) (Fig. 2B). Several factors 
are responsible for glioblastoma development and progression including deficiency 
in cell cycle control, up-regulation of growth factors and their receptors, angiogenic 
alterations, invasion and migration into surrounding tissue, aberrant apoptosis and 
genetic instability. 
 
 
Figure 2. Histology and radiographic MRI images of glioblastoma. (A) Glioblastoma 
histopathological analysis showing (left) necrotic foci (x) which are typically 
surrounded by pseudopalisading tumor cells and microvascular proliferation 
(arrows) (hematoxylin & eosin staining; X100); (right) immunostaining for KI-67 
(brown signal) delineates high mitotic activity (original magnification, X400). (B) T1-
weighted MRI images of a glioblastoma before (left) and after (right) surgery. Yellow 
circles show the area of tumor (left) and the resection cavity after surgery (right). 
Adapted from (Preusser et al., 2011; Redzic et al., 2014). 
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3.1.3 Genetic and molecular profile of glioblastoma 
The accumulation of genetic and epigenetic alterations drives malignant 
transformation towards glioblastoma. Mutations in the metabolic gene IDH1 define 
a small subgroup of glioblastoma patients with favourable prognosis in the radiation 
and/or alkylating chemotherapy era (Table 1). Profiling of glioblastoma from the 
TCGA demonstrated that IDH1 mutation correlates with a subset of tumors 
characterized by the CpG-island methylator phenotype (G-CIMP) (Noushmehr et 
al., 2010), which results in transcriptional silencing of key regulatory genes (Jones 
and Baylin, 2007). IDH-wild-type glioblastomas are often associated with epidermal 
growth factor receptor (EGFR) mutation or amplification, phosphatase and tensin 
homologue (PTEN) mutation or deletion, homozygous deletion of cyclin-dependent 
kinase inhibitor 2A (CDKN2A), amplification or loss of cyclin-dependent kinase 4 
(CDK4), amplification of CDK6, mutation of retinoblastoma-associated protein (RB) 
or telomerase reverse transcriptase (TERT) promoter, methylation of O6-
methylguanine-DNA methyltransferase (MGMT), loss of chromosome 10 and gain 
of chromosome 7, genetic alterations in tumor protein p53 encoding gene (TP53), 
in ATRX as well as in genes encoding histone variant H3.3 (Ichimura et al., 1998; 
Cen et al., 2012; Ohgaki and Kleihues, 2013; Plass et al., 2013) (Table 1 and Fig. 
3). 
 
 
EGFR 
EGFR is a transmembrane glycoprotein which belongs to the ERBB family of 
receptor tyrosine kinases (RTK) (Zaczek et al., 2005). Upon binding to one of the 
EGF family of ligands, EGFR transmits proliferative and pro-survival intracellular 
signals (Oda et al., 2005). EGFR gene amplification and overexpression are found 
in 40% of IDH-wild-type glioblastomas. Amplification of the EGFR gene is frequently 
associated with the EGFR receptor variant III (EGFRvIII), which is characterized by 
a truncated extracellular domain, displaying constitutive ligand-independent activity 
(Wikstrand et al., 1998). EGFRvIII confers tumorigenic potential to glioblastoma 
cells by promoting proliferative, pro-apoptotic and invasive signaling (Gan et al., 
2009). 
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RTK/PI3K/PTEN signaling pathway 
The RTK/phosphoinositide 3-kinase (PI3K)/PTEN signaling cascade is aberrantly 
activated in glioblastoma (80% of the cases). This signaling cascade starts with the 
activation of a wide range of transmembrane RTK including EGFR or platelet-
derived growth factor receptor (PDGFR) involved in recruitment of the cytoplasmic 
mediator PI3K and subsequent activation of downstream effector kinases such as 
protein kinase B (PKB/AKT) and mammalian target of rapamycin (mTOR). Abnormal 
activity in the RTK/PI3K/PTEN cascade has been observed in glioblastoma due to 
amplification or mutations in the key up-stream receptors controlling these 
molecules like EGFR and PDGFR or infrequently in the PI3K gene (less than 10% 
of the cases). Deletion or mutation in the tumor suppressor PTEN are observed in 
40% of IDH-wild-type glioblastomas and associate with constitutive activation of 
PI3K/AKT pathway. Abnormal PI3K/AKT signalling results in disrupted regulation of 
several cellular processes including proliferation, migration, invasion, angiogenesis 
and activity of tumor suppressor pathways like p53 (Brennan et al., 2013). 
 
 
TP53/MDM2/p14ARF pathway  
The TP53 gene encodes for the p53 protein which is stimulated by different cellular 
stressors and triggers anti-proliferative signals (Vogelstein et al., 2000). Aberrant 
p53 activity is frequently observed in IDH-mutant glioblastomas (90% of the case) 
but rare in IDH-wild-type glioblastomas (Watanabe et al., 1996). Different events 
contribute to deregulating the p53 pathway. Amplification and overexpression of the 
p53 inhibitor, murine double minute 2 (MDM2), are also described as affecting 
mainly IDH-wild-type glioblastomas. Finally, loss of alternative reading frame protein 
14 (p14ARF) expression, which binds and blocks MDM-2-dependent degradation of 
p53, is associate with the 50% and the 75% cases of IDH-wild-type and IDH-mutant 
glioblastoma, respectively (Nakamura et al., 2001; Nakada et al., 2011). 
 
 
CDKN2A/CDK4/retinoblastoma 
The tumor suppressor retinoblastoma-associated protein 1 (RB1) is a key regulator 
of the cell cycle and is alterated in around the 80% of glioblastomas. Once 
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phosphorylated by CDK4/cyclin D1 complex, RB1 mediates the release of E2 factor 
(E2F) and consequent induction of genes involved in the cell cycle progression. 
CDKN2A via inhibition of CDK4 prevents the G1-S transition. Thus, deletion in the 
CDKN2A locus, amplification of CDK4 or loss of RB1 are associated with the 
induction of E2F activity and therefore cell proliferation in glioblastoma (Cancer 
Genome Atlas Research, 2008; Ohgaki and Kleihues, 2009).  
 
 
 
Figure 3. Genetic alterations associated with glioblastma. Summary of gene 
sequence modifications and copy number changes for components of the (A) 
RTK/RAS/PI3K, (B) p53 and (C) RB signaling pathways. Activating genetic alterations 
are labeled in red while inactivating alterations are labeled in blue. The type of 
mutation and the percentage of tumors affected are listed. The final percentages of 
glioblastomas displaying alterations in at least one gene of the designated pathway 
are indicated in boxes. Adapted from (Cancer Genome Atlas Research, 2008). 
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3.1.4 Origin of glioblastoma and glioma-initiating cells  
The identification of the cells of origin of glioblastoma still represents a controversial 
field in glioblastoma research. A subset of tumor cells with stem-cell like properties, 
named cancer stem cells (CSC) or glioma-initiating cells (GIC), are currently 
considered as the driving force for glioblastoma development. This concept, 
designed as the CSC hypothesis, follows the idea that GIC originates from 
malignant transformation of neuroglial stem or progenitor cells (Singh et al., 2004; 
Perez Castillo et al., 2008). Alternatively, mature neural cells may also acquire 
mutations and dedifferentiate back to a deregulated stem-like phenotype (Garvalov 
and Acker, 2011) (Fig. 4A). The common anatomical localization of the tumors in 
the brain may support the CSC theory for glioblastoma. The subventricular zone 
(SVZ) of the lateral ventricle (LV) and the subgranular zone (SGZ) of the dentate 
gyrus (DG) represent the two main neurogenic regions where neural stem cells 
(NSC) and neural progenitors originate and may transform in GIC. GIC have been 
proposed to display self-renewal properties, multipotentiality and the capability to 
initiate a tumor with similar parental features after serial orthotopic transplantation 
in mice (Singh et al., 2004; Vescovi et al., 2006). When cultured in serum-free 
neurobasal media (NBM) supplemented with EGF and fibroblast growth factor 
(FGF) these cells grow as non-adherent spheres with the genetic profiles of the 
original glioblastoma specimen and with the potential to generate tumors upon 
intracranial xenografting (Singh et al., 2004; Lee et al., 2006; Ernst et al., 2009). 
Fetal bovine serum inclusion in the culture media induces differentiation of GIC 
across different lineages (Singh et al., 2003). Unlike NSC that permanently 
differentiate upon exposure to serum (Lee et al., 2006), GIC differentiation is 
reversible and they can revert into undifferentiated spheres after serum deprivation 
(Qiang et al., 2009). Defined markers commonly associated with NSC are shared 
and delineate the GIC population. Cluster of differentiation 133 (CD133), a 
glycoprotein expressed by hematopoietic cells and NSC, is the most frequently used 
cell surface marker for identification and isolation of GIC (Uchida et al., 2000; 
Pfenninger et al., 2007). However, the CD133 marker alone has been demonstrated 
to be not sufficient for a proper characterization of GIC; other stemness markers 
including NESTIN, sex determining region Y-box 2 (SOX-2), octamer-binding 
transcription factor-4 (OCT-4), Musashi-1, NANOG, integrin-α6, L1 cell adhesion 
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molecule (L1CAM) and CD15 are used for GIC identification (Persano et al., 2013). 
GIC may be more resistant to irradiation and chemotherapy than non-stem cells, 
thus representing a challenging therapeutic target (Fig. 4B). Microenviromental 
factors and other multiple mechanisms have been defined as responsible for GIC 
maintenance and thus resistance to therapy, however, the molecular mechanisms 
controlling these processes remain poorly understood. GIC are localized within 
specific niches surrounding tumor vessels where by induction of abnormal vascular 
endothelial growth factor (VEGF) secretion as well as by differentiation into 
endothelial-like cells or pericytes (Ricci-Vitiani et al., 2010; Wang et al., 2010; Cheng 
et al., 2013) they may promote angiogenesis and facilitate tumor growth (Bao et al., 
2006; Hamerlik et al., 2012). Due to faster growth of tumor mass than tumor 
vasculature, broad necrotic regions develop near to the perivascular niche, 
generating hypoxic environment with high hypoxia-inducible factor 1-alpha (HIF-1α) 
levels which may also be involved in GIC maintenance (Persano et al., 2013). 
Additionally, the hyperactivation of checkpoint pathways and increased MGMT 
protein levels promote repair of radiation-induced DNA damage rendering GIC 
resistant to therapies (Bao et al., 2006; Hambardzumyan et al., 2008; Pistollato et 
al., 2010; Hsieh, 2011). The GIC population is also maintained by the upregulation 
of different signaling pathways involved in cell growth, differentiation and survival 
such as Notch, c-MET, transforming growth factor-β (TGF-β), nuclear factor-kappa 
B (NF-κB), WNT, EGF, signal transducer and activator of transcription-3 (STAT-3) 
and sonic hedgehog (shh) (Vescovi et al., 2006). A better investigation of these 
signaling pathways might provide insights into the cellular features of GIC and 
improve treatments strategies for glioblastoma. 
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Figure 4. GIC contribute to glioblastoma heterogeneity and resistance to treatment. 
(A) GIC are considered as the cells of origin of glioblastoma. They may derive from 
neural stem, neural progenitors or differentiated CNS cells undergoing epigenetic 
and genetic alterations. GIC expand and acquire diverse genetic alterations 
generating a variety of clones responsible for tumor heterogeneity. (B) The primary 
tumor contains recurrence initiating stem-like cancer (RISC) cells (red circle). Initial 
treatments induce tumor regression, however, subpopulations of RISC cells survive 
therapeutic intervention though intrinsic and adaptive resistance mechanisms. RISC 
cells initiate tumor recurrence through a second round of clonal evolution that 
repopulates the tumor (blue circles). Adapted from (Osuka and Van Meir, 2017). 
 
 25 
 
3.1.5 Heterogeneous nature of glioblastoma 
Glioblastoma encompasses biologically distinct groups characterized by genetic 
and pathologic inter-tumor as well as intra-tumor heterogeneity (Sottoriva et al., 
2013; Inda et al., 2014). The heterogeneous nature of glioblastoma can reflect the 
wide range of possible tumor cells of origin including NSC, astrocytes or 
oligodendroglial progenitor cells (Zong et al., 2015; Osuka and Van Meir, 2017). 
Further diversity may derive from the subsequent acquisition of mutations in these 
cells during tumor progression.  
Recent genomic approaches unveiled the intricacy of tumor heterogeneity in 
glioblastoma. Clonal heterogeneity within subsections of the same tumor reflects 
the glioblastoma evolutionary dynamics at the single patient level. Multiple sampling 
(primary tumor versus recurrent) from different regions of the tumor as well as single 
cell genomic technology paired with next generation sequencing analyses can be 
used to define the evolutionary events during glioblastoma development. Finally, 
these approches can be employed to define the markers of therapeutic resistance 
and tumor recurrence (Sottoriva et al., 2013). 
 
 
3.1.6 Treatment of glioblastoma 
3.1.6.1 Standard of care for glioblastoma 
Glioblastoma remains a fatal disease, with the majority of patients dying within 15-
18 months and in less than 5% of cases after 5 years upon diagnosis (Stupp et al., 
2005; Stupp et al., 2009; Weller et al., 2014; Lu-Emerson et al., 2015). The standard 
of care for glioblastoma consists of maximal surgical resection of the tumor mass 
followed by external beam radiation therapy at 60 Gy in 30-35 fractions and the 
concomitant administration of temozolomide (TMZ) (75 mg/m2/day) followed by 6 
maintenance cycles of TMZ (150-200 mg/m2 in 5 days every 28 days) (Stupp et al., 
2005). TMZ is an orally active DNA alkylating agent of the imidazotetrazine class 
with lipophilic properties enabling its crossing of blood brain barrier (BBB). The 
surgical intent is to execute the largest tumor resection thus facilitating adjuvant 
therapy efficacy (Ryken et al., 2008). The combinatorial treatment of radiotherapy 
plus TMZ has been shown to extend patient survival from 12 to 15 months (Stupp 
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et al., 2005; Huang et al., 2016). TMZ exerts its therapeutic effect by methylation of 
DNA at different positions, e.g., the N-7 or O-6 positions of guanine and N-3 position 
of adenine to form N7-methylguanine (N7-MeG) (70%), O6-methylguanine (O6-MeG) 
(6%) or N3-methyladenine (N3-MeA) (9%). Although less frequently observed, O6-
MeG constitutes the main DNA modification thought to mediate TMZ toxicity (Zhang 
et al., 2011). These different DNA adducts induce DNA mismatch repair 
mechanisms (MMR) in response to DNA damage and therefore cell death 
(Sengupta et al., 2012). Tumor cells influence the TMZ response by the expression 
of proteins with the ability to repair this type of DNA damage. Poly-adenosine 
diphosphate ribose polymerase (PARP) repairs N7-MeG and N3-MeG adducts, 
whereas MGMT repairs O6-MeG lesions (Johnson and Chang, 2012). 
Approximately 35% of glioblastomas exhibit MGMT promoter methylation which 
results in epigenetic silencing of the gene with consequent impairment of DNA repair 
mechanisms and increased sensitivity to TMZ (Weller et al., 2010). MGMT promoter 
methylation thus represents a predictive marker for the efficacy of chemotherapeutic 
agents in glioblastoma (Malmstrom et al., 2012; Wick et al., 2012). Other 
chemotherapeutic agents termed nitrosoureas, including carmustine (BCNU), 
lamustine (CCNU) or mimustine (ACNU) were used before TMZ and are currently 
considered as treatment options mainly for recurrent glioblastoma (Weller et al., 
2014). 
 
 
3.1.6.2 Glioblastoma resistance to targeted therapies and innovative 
treatment strategies 
Despite the standard multimodal therapeutic approach, glioblastoma recurrence is 
common and associated with poor prognosis. Negligible therapeutic success have 
been achieved over the past several decades and treatment options for relapsed 
glioblastoma remain limited (Weller et al., 2015). Multiple factors are responsible for 
the therapeutic resistance and relapse in glioblastoma: (1) the presence of a patially 
intact BBB regulating drug delivery; (2) the highly invasive and heterogeneous 
nature of the tumor; (3) aberrant activation of DNA repair mechanisms; (4) the 
existence of a sub-population of cells with stem-like properties. More recently, the 
evaluation of novel therapeutic strategies has received increasing attention. 
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Glioblastoma is a highly vascularised tumor and expresses high levels of VEGF, the 
major angiogenic driver. Bevacizumab, a humanized monoclonal antibody against 
VEGF, has been approved by the U.S. FDA for recurrent glioblastoma in 2009 
(Cohen et al., 2009), but not in the European Union (E. U.). However, the results of 
two large randomized phase III trials - RTOG 0825 (Gilbert et al., 2014) and AVAGlio 
(Chinot et al., 2004), showed that bevacizumab together with standard therapy 
improves progression-free survival but not overall survival in newly diagnosed 
glioblastoma.  
Thereutic approaches targeting EGFR have also been investigated for glioblastoma. 
Several clinical trials tested EGFR inhibitors including monoclonal antibodies 
(cetuximab), tyrosine kinase inhibitors (gefitinib or erlotinib) and EGFRvIII-targeted 
vaccines. Despite the discouraging results observed upon conclusion of these trials, 
EGFR, as a therapeutic agent in glioblastoma, is still under consideration (Reardon 
et al., 2014). In recent years, novel immunotherapeutic approaches have been 
regarded as promising. Substantial work has shown that glioblastoma cells establish 
an immunosuppressive environment, which impairs T cell effector function. 
Targeting glioblastoma-induced immunosuppressive networks has been shown to 
significantly prolong survival in experimental glioma models, prompting further 
investigation in glioblastoma patients (Sampson et al., 2014; Reardon et al., 2016). 
Indeed, several clinical trials employing these molecules are ongoing (Weiss et al., 
2015), for instance, clinical trials using (i) immune checkpoint blockade by cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) 
inhibitors, (ii) genetically engineered, autologous cytotoxic T lymphocyte (CTL) 
therapy with vectors encoding T-cell receptors (TCR) or chimeric antibody receptors 
(CAR), (iii) autologous tumor lysate-pulsed dendritic cell vaccination (Prins et al., 
2013; Rushworth et al., 2014; Lim et al., 2016). Evidence from other tumor entities 
indicates that biomarker-based patient stratification increases immunotherapy 
efficacy (Schumacher et al., 2015). Therefore, understanding which patients may 
benefit from a specific immunotherapy treatment may result in improved clinical 
responses in the near future. Other therapy modalities under investigation include 
gene therapy, peptide and dendritic cell vaccines, synthetic chlorotoxins, 
radiolabelled drugs and antibodies (Quang and Brady, 2004; Rich and Bigner, 2004; 
Mamelak et al., 2006; Reardon et al., 2006; Ferguson and Lesniak, 2007; Fulci and 
Chiocca, 2007). 
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In order to improve the design of targeted therapies in glioblastoma it might be 
necessary to better understand the dynamics of tumor progression, the role of 
different genetic alterations for response to therapy, the cross-talk between altered 
pathways as well as the network of interactions between tumor cells and the 
microenvironment. Additionally, molecular profiling of different tumor regions before 
and after therapy together with the analysis of tumour and/or circulating glioma cells 
from responders versus nonresponders patients might result in to the identification 
of biomarkers for individualized treatment (Adamczyk et al., 2015; Reifenberger et 
al., 2016). 
 
 
3.2 Transforming growth factor (TGF)-β 
3.2.1 Synthesis of the TGF-β superfamily of ligands  
TGF-β ligands represent the prototypic molecules of a superfamily of 
interconnected cytokines containing more than 30 members in human (Lander et 
al., 2001). The TGF-β superfamily of cytokines can be classified with respect to 
sequence similarities and function into two groups: (i) the TGF-β-like group that 
contains TGF-β, activin and nodal as well as (ii) growth and differentiation factors 
(GDF)/bone morphogenetic proteins (BMP)-like group constituted by BMP, GDF 
and anti-Mullerian hormone (AMH) (Shi and Massague, 2003). TGF-β ligands 
control several cellular processes such as morphogenesis, proliferation, 
differentiation, death, cytoskeletal organization, adhesion and migration (Massague, 
2012). TGF-β is initially synthesized as a pre-pro-TGF-β monomeric 55 kDa 
precursor which is composed of a large amino-terminal signal peptide (SP), a region 
termed latency-associated peptide (LAP), and a carboxy-terminal portion containig 
the active form of TGF-β (Harrison et al., 2011). SP cleavage and dimerization of 
two TGF-β monomers generates pro-TGF-β (Gentry et al., 1988; Brunner et al., 
1989). Enzymes like furin convertase catalyze the cleavage of pro-TGF-β into the 
small latent TGF-β complex (SLC) comprised by two TGF-β chains connected with 
two LAP chains by non-covalent interactions (Rifkin, 2005; Todorovic et al., 2005). 
A covalent binding of the latent TGF-β binding protein (LTBP) to the SLC yields the 
formation of the large latent TGF-β complex (LLC) (Gleizes et al., 1996; Saharinen 
et al., 1996; Saharinen and Keski-Oja, 2000; Chen et al., 2005). LCC is then 
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secreted from cells into the extracellular space where the N-terminal region of LTBP 
forms covalent interactions with the extracellular matrix (ECM) and controls TGF-β 
availability (Fig. 5). The release of the LLC from the ECM and the delivery of mature 
TGF-β from the LAP are crucial steps for TGF-β functional activation and interaction 
with affiliate cell-surface receptors. The conversion into active TGF-β involves 
different proteases such as plasmin, matrix metalloproteinase -2/- 9 (MMP -2/-9), 
gelatinase, BMP-1, thrombospondin 1 (THBS1) that cleave LAP to release 25 kDa 
bioactive TGF-β (Sato and Rifkin, 1989; Flaumenhaft et al., 1992; Kojima et al., 
1993; Schultz-Cherry et al., 1994; Yu and Stamenkovic, 2000; Ge and Greenspan, 
2006; Koli et al., 2008). Conformational changes in the LLC bound to integrins 
represent another way by which mature TGF-β can be released (Wipff and Hinz, 
2008). Three TGF-β mature ligands, TGF-β1, TGF-β2 and TGF-β3, have been 
reported in humans (Massague, 2000). These ligands share 70-80% structural 
homology but mediate different functions at least during development and their 
expression is different among tissues (Wu and Hill, 2009). Tgf-β1 knock-out mouse 
models die due to defects in vasculature (Martin et al., 1995). Ablation of mouse 
Tgf-β2 results in embryonic death due to cardiac defects (Sanford et al., 1997; 
Bartram et al., 2001) and Tgf-β3 knock-out mice have malformed cleft palate (Taya 
et al., 1999). 
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Figure 5. Illustration of the extracellular processing of latent TGF-β. TGF-β ligands 
are synthesized as part of a large latent TGF-β complex (LLC) formed by mature 
dimeric TGF-β and its latency-associate peptide (LAP) connected to a latent TGF-β 
binding protein (LTBP). Adapted from (Gressner et al., 2002). 
 
 
3.2.2 TGF-β family of receptors  
TGF-β superfamily members signal by a heteromeric complex composed of TGF-β 
receptor type II (TGF-βRII) and type I (TGF-βRI) transmembrane serine/threonine 
kinase receptors. Five TGF-βRII and seven TGF-βRI have been found in humans. 
TGF-βRII and TGF-βRI are transmembrane glycoproteins containing an N-terminal 
ligand-binding extracellular domain linked by a transmembrane region to the C-
terminal intracellular domain with the kinase activity (Okadome et al., 1994; Hinck, 
2012). TGF-βRII has a molecular weight of 75 kDa and is the product of a gene 
located on chromosome 3p22 (Lin et al., 1992; Mathew et al., 1994). TGF-βRI has 
a molecular weight of 53 kDa and is encoded by a gene located on chromosome 
9q22 (Boyd and Massague, 1989; Pasche et al., 1998). Although the ligand-receptor 
interactions have not been completely elucidated for all TGF-β superfamily ligands, 
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the formation of a heteromeric complex composed of two TGF-βRII, two TGF-βRI 
and a dimeric ligand is universal and widely accepted. This active receptor complex 
allows the constitutively active TGF-βRII to phosphorylate and thus activate the 
TGF-βRI on the GlySer (GS) domain (Wrana et al., 1994; Manning et al., 2002; 
Wakefield and Hill, 2013). Membrane-anchored co-receptors such as the TGF-β 
receptor type III (TGF-βRIII) (also known as betaglycan) and endoglin modulate the 
availability of TGF-β superfamily of ligands and add complexity to the regulation of 
ligand/receptor activation (Lopez-Casillas et al., 1991; Bernabeu et al., 2009). The 
seven different TGF-βRI are distinguished into two groups based on whether they 
transmit the signal to the TGFβ-like or BMP-like SMAD proteins (Weiss and 
Attisano, 2013). In addition to SMAD, TGF-β superfamily members transmit signals 
via non-canonical pathways including various branches of mitogen-activated protein 
kinase (MAPK) cascades, Rho-like GTPase signaling pathways and PI3K/AKT 
pathways. 
 
 
3.2.3 Signaling pathways induced by the TGF-β superfamily 
SMAD proteins are cytosolic mediators involved in the so-called TGF-β canonical 
signaling pathway. The human genome encodes eight different members of the 
SMAD family, which are functionally separated into three groups: receptor-activated 
SMAD (R-SMAD), common mediator SMAD (Co-SMAD) and inhibitory SMAD (I-
SMAD) (Luukko et al., 2001). The R-SMAD group comprises SMAD1/2/3/5/8 which 
are phosphorylated by the TGF-βRI; SMAD4 is a Co-SMAD that oligomerises with 
activated R-SMAD and allows their nuclear translocation. The I-SMAD group 
comprises SMAD6/7 which are also induced by TGF-β family members but 
negatively interfere with TGF-β signaling (Imamura et al., 1997). SMAD proteins 
display two conserved domains, the N-terminal Mad homology 1 (MH1) and the C-
terminal Mad homology 2 (MH2) domains (Massague et al., 2005). The MH1 domain 
is conserved among R-SMAD and Co-SMAD but it is missing in I-SMAD. The MH1 
domain is involved in the interactions with DNA and thus controls SMAD nuclear 
translocation and gene induction. All SMAD have a highly conserved MH2 domain 
which is involved in SMAD oligomerisation, recognition by TGF-βRI and interaction 
with adaptors and transcription factors (Fig. 6).  
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Figure 6. Structural and functional role of SMAD elements. SMAD proteins have MH1 
and MH2 domains. The MH1 domain contains a β-hairpin structure for DNA binding. 
I-SMAD lack a MH1 domain. The linker region of SMAD4 contains a nuclear export 
signal. The MH2 basic pocket in SMAD interacts with activated TGF-βR. The MH2 
basic pocket in SMAD4 allows the binding with the pS-x-pS motif (SxS) of R-SMAD 
(Derynck and Zhang, 2003). 
 
 
TGF-β canonical signaling starts with ligand binding to the extracellular domain of 
the TGF-βRII and consequent transphosphorylation of TGF-βRI (Wrana et al., 1994; 
Wakefield and Hill, 2013). The activated TGF-βRI recruits and phosphorylates the 
R-SMAD proteins. In general, the binding of TGF-β ligands promotes a 
characteristic combination of different TGF-βRII and TGF-βRI receptors on the 
plasma membrane (Shi and Massague, 2003; Massague et al., 2005). TGF-β, 
activin and nodal induce the activation of a receptor complex composed of TGF-
βRII or activin receptor 2 (ACVR2) and TGF-βRI (e.g. activin-receptor-like kinase 
ALK-4, ALK-5 and ALK-7) which signals via SMAD2/3. In contrast, SMAD1/5/8 are 
induced upon the binding of BMP ligands to a complex of receptors formed by BMP 
type II receptor (BMPRII) or ACVR2 and TGF-βRI (ALK1/2/3/6) (Fig. 7).  
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Figure 7. Schematic interactions of TGF-β family members with their specific Type II 
and Type I receptors as well as R-SMAD. Adapted from (Derynck and Zhang, 2003; 
Massague et al., 2005). 
 
 
Once phosphorylated, R-SMAD proteins detach from the receptor complex and 
associate with the common mediator SMAD4 within the cytoplasm (Massague, 
1998; Lebrun et al., 1999; Jayaraman and Massague, 2000). The R-SMAD/SMAD4 
complex translocates into the nucleus where it recognizes the DNA sequence 
CAGAC, named SMAD binding element (SBE), and regulates specific target 
transcription. SMAD proteins bind with less affinity to some GC-rich sequences (Shi 
et al., 1998). The association of SMAD with transcriptional coactivators or 
corepressors results in the induction or inhibition of their target gene (Massague et 
al., 2005). I-SMAD execute a negative regulation of TGF-β signaling either by 
preventing phosphorylated R-SMAD/Co-SMAD interactions or by activation of 
SMAD specific E3 ubiquitin protein ligase (SMURF) (Imamura et al., 1997; Nakao 
et al., 1997; Hata et al., 1998; Kavsak et al., 2000; Itoh and ten Dijke, 2007). TGF-
β/SMAD signaling regulates cell growth, differentiation, apoptosis, migration and 
invasion/metastasis (Proetzel et al., 1995; Sanford et al., 1997; Goumans and 
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Mummery, 2000; Massague, 2000). Alterations in the TGF-β canonical pathway 
occur in several human diseases, such as hereditary hemorrhagic telangectasia, 
fibrotic diseases, atherosclerosis, hereditary synostosis, hereditary 
chondrodysplasias, cleidocranial dysplasia and familial primary pulmonary 
hypertension (Akhurst and Hata, 2012). Additional diversity in TGF-β signaling is 
achieved via activation of the non-canonical SMAD-independent pathways. Non-
SMAD signaling includes tumor necrosis factor (TNF) receptor-associated factor 4/6 
(TRAF4/6), TGFβ-activated kinase 1 (TAK1), p38 MAPK, PI3K-AKT, extracellular 
signal-regulated kinase (ERK), JUN amino-terminal kinase (JNK) and NF-κB 
(Akhurst and Hata, 2012) (Fig. 8). Finally, WNT, Hedgehog, Notch, interferon, TNF 
and RAS pathways also contribute to the complexity of cellular responses generated 
by TGFβ superfamily members. The dynamic interconnection between canonical 
and non-canonical signaling cascades can affect the output of TGF-β signaling 
between growth suppression and induction of cellular plasticity (Massague and 
Gomis, 2006). In human cancer, TGF-β signaling exerts a dual role: in the early 
phase of tumorigenesis it may act as inhibitor of tumor development (Massague, 
2000), but later on these suppressive functions are lost, and the TGF-β pathway 
turns to promote tumor progression, invasion, dissemination/metastasis, and 
immune evasion (Massague, 2008). Gene expression programmes controlled by 
TGFβ signaling pathways may provide tumor-suppressive or tumor-promoting 
functions depending on the tumor type and the stage of tumor progression (Akhurst 
and Hata, 2012). Thus, the functional outcome of the TGF-β response is context-
dependent and determined by the cell, type and its state of activation.  
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Figure 8. Schematic representation of TGF-β signaling pathways. Active TGF-β 
dimers induce the formation of TGF-β receptor type II (TβRII)/TGF-β receptor type I 
(TβRI) heteromeric complex. TβRII then transphosphorylates TβRI, which transmits 
intracellular signaling via R-SMAD phosphorylation. R-SMAD proteins interact with 
SMAD4 and translocate into the nucleus to regulate the expression of specific 
targets. In the non-canonical pathways, the activated TβR complex signals through 
other factors, such as TRAF4/6, TAK1, p38 MAPK, PI3K/AKT, ERK, JNK or NF-κB. 
TGF-β signaling can be influenced by other pathways than the canonical and non-
canonical TGFβ signaling, such as WNT, Hedgehog, Notch, interferon, TNF and RAS 
pathways.  
 
 
3.2.4 The role of TGF-β in glioblastoma 
The TGF-β pathway is considered a crucial mediator of glioblastoma pathogenesis 
due to its control of cell proliferation, tumor invasion, angiogenesis, 
immunosuppression and the maintenance of GIC population (Ueki et al., 1992; 
Alexandrow and Moses, 1995; Wesolowska et al., 2008; Ikushima et al., 2009) (Fig. 
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9). Glioblastoma patients show high level expression of TGF-β which has been 
linked to poor prognosis (Bruna et al., 2007; Hau et al., 2011). Recent data from our 
laboratory, however, challenge this view (Frei et al., 2015). PDGF-B upregulation by 
aberrant TGF-β/SMAD signaling may lead to tumor cell proliferation (Seoane et al., 
2004; Bruna et al., 2007). TGF-β promotes cell invasion by increasing the 
expression of MMP or suppressing tissue inhibitors of metalloproteinase (TIMP) 
(Wick et al., 2001). Additionally, TGF-β upregulates micro RNA (miR) -10a/-10b 
expression, which may promote migration of glioma cells via inhibition of PTEN (Liu 
et al., 2013). The pro-angiogenic effect of TGF-β arises from its stimulatory effect 
on the expression of angiogenic factors including VEGF, FGF and plasminogen 
activator inhibitor (PAI-1) (Dieterich et al., 2012; Mangani et al., 2016). In this 
context, TGF-β signaling induces insulin-like growth factor-binding protein 7 
(IGFBP7), a tumor vessel biomarker associated with glioblastoma (Pen et al., 2008). 
TGF-β and other tumor-secreted cytokines generate an immunosuppressive 
glioblastoma microenvironment through a variety of mechanisms (Zhu et al., 2012). 
For instance, TGF-β2 decreases human leukocyte antigen D related (HLA-DR) 
promoting immune escape of tumor cells from T cell attack (Zuber et al., 1988). 
Moreover, TGF-β inhibits the expression of perforin, granzyme A, granzyme B, 
Interferon-γ, and Fas ligand, which are co-responsible for cytotoxic T lymphocyte 
(CTL)-mediated tumor cytotoxicity (Thomas and Massague, 2005). 
Immunosuppressive regulatory T (T-reg) cells and cytokine interleukin-10 (IL-10) 
expression are also promoted by TGF-β (Maeda et al., 1995; Chen et al., 2005). 
Furthermore, TGF-β immunosuppressive function includes a reduction of the 
activating immune cell receptor natural killer group 2, member D (NKG2D) in CD8+ 
T cells and natural killer (NK) cells, reducing the lytic activity of these cells against 
glioma cells (Friese et al., 2004; Ikushima et al., 2009). TGF-β may be more 
abundant in GIC than undifferentiated glioma cells (Qiu et al., 2011). High TGF-β 
signaling endorses DNA damage responses in GIC thus rendering this population 
resistant to DNA damaging agents (Hardee et al., 2012). TGF-β is also involved in 
the induction of stem cell marker essential for GIC maintenance. Inhibition of TGF-
β signaling was shown to be associated with the decrease in the expression of SOX-
2 with consequent reduction of GIC stem-like properties (Ikushima et al., 2009). 
Moreover, TGF-β-SMAD signaling can up-regulate the leukemia inhibitory factor 
(LIF) leading to the activation of the JAK-STAT signaling pathway involved in self-
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renewal capacity of GIC (Penuelas et al., 2009). Finally, the inhibition of TGF-βRI 
abrogates the ability to initiate tumors in the CD44 high/DNA binding protein inhibitor 
(Id1) high GIC population (Anido et al., 2010). 
 
 
 
Figure 9. TGF-β signaling in gliomagenesis. The TGF-β pathway promotes 
glioblastoma via induction of different pro-tumorigenic signals: proliferation via 
PDGF-B and miR-182; invasiveness via miR-182, miR-10 and MMP; angiogenesis via 
VEGF, IGFBP7 and JNK. TGF-β exerts an immunosuppressive role by inhibiting NK 
cells, CTL, dendritic cells (DC), and by T-reg cells. In addition, the TGF-β pathway 
maintains the GSC population via LIF, SOX-4/SOX-2 axis, and ID1-ID3. Adapted from 
(Han et al., 2015). 
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3.3 Hepatocyte growth factor (HGF)/c-MET  
3.3.1 Structure and functions of HGF and its receptor c-MET  
c-MET is a cell surface RTK encoded by a gene located on chromosome 7q21-31. 
Its expression is reserved to epithelial cells of different organs, including liver, 
pancreas, prostate, kidney, muscle and bone marrow, both during embryogenesis 
and adulthood (Comoglio et al., 2008). c-MET is produced upon proteolytic 
processing of its precursor in the post-Golgi compartment. Mature c-MET receptor 
consists of a single-pass α/β heterodimer composed by a completely extracellular 
α-subunit linked by a disulphide bond to a transmembrane β-subunit displaying 
intracellular catalytic activity (Fig. 10A) (Trusolino and Comoglio, 2002). The 
extracellular part of c-MET includes three functional domains: the semaphorin 
(sema) domain, which encompasses the whole α-subunit and part of the β-subunit, 
the plexin-semaphorin-integrin (PSI) domain composed by four disulphide bonds 
and four immunoglobulin-plexin-transcription (IPT) domains. The intracellular 
segment is formed by three domains: a juxtamembrane sequence that negatively 
controls the kinase activity when phosphorylated on Ser975, a catalytic region that 
positively controls kinase activity upon trans-phosphorylation of Tyr1234/1235 and 
a carboxy-terminal multifunctional docking site that contains two tyrosines 
(Tyr1349/1356) involved in the recruitment of several transducers and adaptors 
(Trusolino et al., 2010). HGF, also known as scatter factor, is the ligand of c-MET 
(Stoker et al., 1987; Nakamura, 1989; Weidner et al., 1991). HGF broadly distributes 
in the ECM of different tissues where is sequestered in its inactive form by heparin-
like proteoglycans (Kobayashi et al., 1994; Lyon et al., 1994). The principal sources 
of HGF secretion are mesenchymal cells. HGF is produced as a biologically inactive 
single-chain precursor further converted into a disulphide linked α/β chains active 
heterodimer by extracellular proteases (Fig. 10B). The α-chain contains an amino-
terminal hairpin loop (HL) and four kringle domains (k1-k4). The β-chain is formed 
of a serine protease homology (SPH) domain without proteolytic activity. HGF is a 
pleiotropic cytokine, involved in induction of cell proliferation, survival, motility, 
scattering, differentiation and morphogenesis (Trusolino and Comoglio, 2002; 
Birchmeier et al., 2003; Basilico et al., 2008). The cell-scattering phenotype, a key 
epithelial function during embryogenesis and wound repair, is characterized by 
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destruction of the cadherin-based cell-cell contacts and consequent cell motility 
(Corso et al., 2005). This process is also crucial for the long-range migration of 
skeletal muscle progenitor cells during embryogenesis. Indeed, mutant mice with 
ablation HGF- or c-MET-dependent signals exhibit different deficits that are related 
to reduction in proliferative signals. c-Met or Hgf knockout mouse embryos show 
significant reduction in liver size. Moreover, abnormal placental development in Hgf 
and c-Met knockout mice leads to death of the embryos in utero (Schmidt et al., 
1995; Uehara et al., 1995). 
 
Figure 10. Domain structure of c-MET and HGF. (A) c-MET is synthesized upon 
proteolytic processing of a precursor into a single-pass, disulphide-linked α/β 
heterodimer. The extracellular portion of c-MET is composed of three domain types. 
The N-terminal is formed by a SEMA domain, the PSI domain and four IPT domains. 
The C-terminal part contains a tyrosine kinase catalytic domain flanked by 
juxtamembrane and carboxy-terminal sequences. The Y1234/1235 residues on the 
kinase catalytic domain positively modulate the enzyme activity, while the 
juxtamembrane Y1003 negatively regulates c-MET. Y1349/1356 tyrosines are 
multifunctional docking sites recruiting transducers and adaptors. (B) HGF is 
produced as a single-chain precursor and then converted into its active form upon 
cleavage of the bond between Arg494 and Val495 by extracellular proteases. Mature 
HGF is composed of a disulphide linked α/β-chain. Adapted from (Organ and Tsao, 
2011). 
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3.3.2 HGF/c-MET signaling pathway 
HGF/c-MET signaling is initiated by the binding of HGF to the amino-terminal region 
of c-MET and consequent receptor homodimerization and phosphorylation on the 
two Y1234/1235 residues (Rodrigues and Park, 1994) (Fig. 11). This is followed by 
the phosphorylation of two additional Y1349/1356 residues of the c-MET carboxy-
terminal tail (Ponzetto et al., 1994) and the recruitment of several effector molecules 
such as: growth factor receptor-bound protein 2 (GRB2) (Fixman et al., 1996), src 
homology 2 domain-containing (SHC) (Pelicci et al., 1995), v-crk sarcoma virus 
CT10 oncogene homolog (CRK), CRK-like (CRKL) (Garcia-Guzman et al., 1999; 
Sakkab et al., 2000), PI3K, phospholipase Cγ (PLCγ), v-src sarcoma (Schmidt et 
al., 1999) viral oncogene homolog (SRC) (Ponzetto et al., 1994), src homology 2 
domain-containing phosphatase 2 (SHP2) (Schaeper et al., 2000; Maroun et al., 
2003) and STAT-3 (Boccaccio et al., 1998; Zhang et al., 2002). Unique for c-MET is 
the binding of the multiple adaptor protein termed GRB2-associated binding protein 
1 (GAB1) (Weidner et al., 1996). GAB1 associates either directly or through GRB2 
to phosphorylated c-MET and allows the formation of binding sites for more 
downstream adaptors. This machinery activates different downstream signal 
transduction pathways that include MAPK cascades, JNK, p38, PI3K-AKT axis, 
focal adhesion kinase (FAK) and the inhibitor of NF-κB (IκBα)/NF-κB complex 
(Maroun et al., 1999; Sipeki et al., 1999; Maroun et al., 2000; Lai et al., 2009). The 
sum of these signaling pathways controls different processes such as cell 
proliferation, survival, motility, scattering, differentiation and morphogenesis 
(Trusolino and Comoglio, 2002; Birchmeier et al., 2003; Basilico et al., 2008). 
Different signals play a negative control for c-MET activation. c-MET 
phosphorylation on the Y1003 residue has an inhibitory effect on the c-MET pathway 
(Peschard et al., 2001; Petrelli et al., 2002). Several protein tyrosine phosphatases 
(PTP) are involved in c-MET dephosphorylation and its consequent inactivation 
(Palka et al., 2003; Machide et al., 2006). Finally, protein kinase C (PKC) blocks c-
MET activity (Gandino et al., 1990; Gandino et al., 1994). Increased levels of 
intracellular calcium can also have a negative effect on c-MET (Gandino et al., 
1991). Additional complexity is generated by the association of c-MET with co-
receptors at the cell surface, influencing the outcome of c-MET dependent signalling 
(Trusolino et al., 2010). 
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Figure 11. c-MET signaling adaptors and mediators. Active c-MET recruits signaling 
effectors including GRB2, SHC, CT10, CRK and CRKL and the effector molecules 
PI3K, PLCγ, SRC, SHP2 and STAT-3. In addition, the multi-adaptor protein GAB1 
bound to phosphorylated c-MET forms binding sites for other downstream adaptors. 
The downstream response to c-MET activation is similar to many RTK and include 
cell proliferation, survival, motility, scattering, differentiation and morphogenesis. 
Adapted from (Organ and Tsao, 2011). 
 
 
3.3.3 HGF/c-MET signaling in glioblastoma 
Although genetic alterations in c-MET rarely occur in glioblastoma (4%), a crucial 
role for the c-MET pathway has been attributed in glioblastoma pathogenesis since 
c-MET is often overexpressed together with its ligand (Koochekpour et al., 1997). 
HGF and c-MET are also expressed by endothelial cells and may contribute to 
glioblastoma neoangiogenesis. Aberrant activation of c-MET promotes proliferation 
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in glioblastoma via activation of c-MYC-dependent G1/S cell cycle progression 
(Walter et al., 2002). c-MET prevents DNA damage-induced cell death and 
promotes survival of glioblastoma cells (Bowers et al., 2000). The role of HGF/c-
MET in glioblastoma invasive growth is well recognised (Brockmann et al., 2003). 
Invasion and migration of glioblastoma cells are supported by HGF dependent 
induction of MMP-2 and urokinase-type plasminogen activator (uPA) expression 
(Hamasuna et al., 1999). In addition, c-MET activity has been associated with 
glioblastoma stem-like properties, including glioblastoma resistance to therapies 
and tumor progression (Joo et al., 2012). Active c-MET up-regulates the expression 
of a panel of transcription factors, including SOX-2, c-MYC, kruppel-like factor-4 
(KLF-4), OCT-4, and NANOG, involved in reprogramming differentiated cells into 
pluripotent stem cells (Li et al., 2011). Several studies support a role for c-MET in 
the regulation of the glioblastoma stem cell phenotype and described a correlation 
between c-MET levels and tumorigenic potential of glioblastoma (De Bacco et al., 
2012; Joo et al., 2012). 
 
 
3.4 Targeting TGF-β or c-MET pathways for glioblastoma therapy  
To date, there are 10 different registered trials targeting TGF-β or HGF/c-MET 
pathways in glioblastoma patients (Table 2). Table 2 lists the summary of (A) TGF-
β and (B) HGF/c-MET clinical trials. Due to the high level of complexity 
characterizing glioblastoma, only a subset of patients may respond to these 
inhibitory strategies. It is therefore crucial to elucidate biomarkers defining sensitivity 
to TGF-β or c-MET targeting in glioblastoma. The current research knowledge 
supports the combination of TGF-β or HGF/c-MET blockade with cytotoxic therapies 
such as radiotherapy and chemotherapy or anti-angiogenic therapies. In addition, 
interconnections among the multiple pathways and the presence of compensatory 
mechanisms lead to treatment resistance in glioblastoma. The use of combination 
therapies that concurrently target multiple pathways are likely to reach superior 
therapeutic efficacy. However, the interactions between oncogenic pathways 
remain poorly understood, and further studies are needed for defining novel and 
more efficient combination therapies in glioblastoma. 
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Table 2. List of the clinical trials targeting (A) TGF-β or (B) HGF/c-MET signaling 
pathways in glioblastoma. Data from www.clinicaltrials.gov. 
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4. Materials and Methods 
Reagents 
EMD1214063 is a highly specific, reversible and ATP-competitive, small molecule 
c-MET tyrosine kinase inhibitor developed by Merck Serono (Darmstadt, Germany) 
(Bladt et al., 2013). SD-208 (Scios Inc., Sunnyvale, CA) is a TGF-βRI (ALK-5) 
inhibitor (Uhl et al., 2004). Galunisertib (LY2157299 monohydrate) is a TGF-βRI 
(ALK-5) inhibitor (Selleckchem, Houston, TX). U0126 is a highly selective inhibitor 
of MEK1 and MEK2 (Cell Signaling Technology, CST Denvers, MA). AZD5363 is a 
serine/threonine protein kinase and protein kinase B alpha inhibitor (AstraZeneca, 
Cheshire, UK). All drugs were dissolved in dimethylsulfoxide (DMSO) and further 
diluted in cell culture medium (final solvent concentration <0.001%). Recombinant 
human HGF, human TGF-β1 and TGF-β2 (R&D Systems, Minneapolis, MN) were 
dissolved in Dulbecco's phosphate-buffered saline (PBS). 
 
Cell culture 
ZH-161, ZH-305 and T-269 GIC lines were isolated from surgically removed de novo 
glioblastomas (Lemke et al., 2014; Seystahl et al., 2015). Glioblastoma tissue 
samples were washed with Hanks' balanced salt solution (Invitrogen, Carlsbad, CA), 
and digested with 1 mg ml−1 collagenase/dispase (Roche, Mannheim, Germany) for 
30 min at 37 °C. After digestion, the fragments were filtered using a 70 μm cell mesh 
(Sigma-Aldrich, St Louis, MO), and then 2,500-5,000 cells  were plated into T25 
flasks. The cells were cultured in neurobasal medium (NBM) supplemented with 2% 
B27, 1% glutamine, EGF (10 ng/ml) and basic FGF (20 ng/ml). Spheres with 
diameters from 200-500 μm were dissociated mechanically for further passaging. 
The cell lines are routinely evaluated for self-renewal capacity, stem cell marker 
expression, and in vivo tumorigenicity in nude mice. 
 
Real-time polymerase chain reaction (RT-PCR) 
Total mRNA extraction was performed using the NucleoSpin®RNA II system 
including DNase treatment (Macherey-Nagel, Düren, Germany). cDNA was 
prepared using the iScript™ cDNA synthesis kit (Biorad Laboratories, Reinach, 
Germany) and random primer 9 (New England Biolabs, Ipswich, MA). For RT-PCR, 
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gene expression was measured using SYBR Green chemistry (AppliChem, 
Darmstadt, Germany) with the Real Time PCR System 7300 (Applied Biosystems, 
Foster City, CA). The conditions for RT-PCR were 40 cycles, 95°C/15 sec, 60°C/1 
min. Specific target gene expression was normalized to hypoxanthine-guanine 
phosphoribosyltransferase 1 (HPRT1). The following primers were used: HPRT1 
(forward 5'-TGA GGA TTT GGA AAG GGT GT-3', reverse 5'-GAG CAC ACA GAG 
GGC TAC AA-3'); HGF (forward 5'-CCG AAC AGG ATT CTT TCA CC-3', reverse 
5'-AGG AGG AGA TGC AGG AGG AC-3'); c-MET (forward 5'-ATG GAA ATG CCT 
CTG GAG TG-3', reverse 5'-CTG AGA TAC GCA GCC TGA AG-3'); OCT-4 (forward 
5'-CGA GAA GGA TGT GGT CCG AG-3', reverse 5'-TGT GCA TAG TCG CTG CTT 
GA-3'); SOX-2 (forward 5'-CAC ACT GCC CCT CTC AC-3', reverse 5'-TCC ATG 
CTG TTT CTT ACT CTC-3'); NANOG (forward 5'-GAA ATA CCT CAG CCT CCA 
GC-3', reverse 5'-GCG TCA CAC CAT TGC TAT TC-3'); PAI-1 (forward 5'-CAG 
AAA GTG AAG ATC GAG GTG AA C-3', reverse 5'-GGA AGG GTC TGT CCA TGA 
TGA A-3'); ALK-5 (forward 5'-CTG GGA AAT TGC TCG ACG ATG-3', reverse 5'-
ACT CTC AAG GCT TCA CAG CTC-3'); TGF-β1 (forward 5'-GCC CTG GAC ACC 
AAC TAT TG-3', reverse 5'-CGT GTC CAG GCT CCA AAT G-3'); TGF-β2 (forward 
5'-AAG CTT ACA CTG TCC CTG CTG C-3', reverse 5'-TGT GGA GGT GCC ATC 
AAT ACC T-3'); TGF-β3 (forward 5'-TCA GCC TCT CTC TGT CCA CTT-3', reverse 
5'-CAT CAC CGT TGG CTC AGG G-3'); SMAD2 (forward 5'-GCA CTT GCT CTG 
AAA TTT GGG C-3', reverse 5'-GAC GAC CAT CAA GAG ACC TGG-3'); SMAD3 
(forward 5'-GCC TGT GCT GGA ACA TCA TC-3', reverse 5'-TTG CCC TCA TGT 
GTG CTC TT-3'); SMAD4 (forward 5'-GGT TCC TTC AAG CTG CCC TA-3', reverse 
5'-ATG TGC AAC CTT GCT CTC TCA-3'). 
 
Immunoblot analysis 
Whole cell lysates were prepared using radio-immunoprecipitation assay (RIPA) 
lysis buffer (pH 7.8) containing 25 mM Tris-HCl, 120 mM NaCl, 5 mM EDTA and 
0.5% NP-40 supplemented with 2 μg/mL aprotinin, 10 μg/mL leupeptin, 100 μg/mL 
phenylmethylsulfonyl fluoride (Sigma Aldrich), 200 mM sodium orthovanadate, 0.5 
M NaF, protease inhibitor cocktail sets III and IV (Sigma Aldrich) and phosphatase 
inhibitor cocktails 2 and 3 (Sigma Aldrich). Protein levels were determined using the 
Thermo Scientific Pierce bicinchoninic acid assay (BCA) protein assay kit. Equal 
 46 
 
protein concentrations (25 μg) were loaded and electrophoresis was performed on 
SDS-PAGE (8-10%) under reducing conditions (5% v/v, final concentration 2-
mercaptoethanol). After electrophoresis, the separated proteins were transferred to 
nitrocellulose (Bio-Rad) membranes. Next, the membranes were blocked to avoid 
nonspecific binding of antibodies in TBST containing 5% skim milk or 5% bovine 
serum albumin (BSA) and incubated overnight at 4°C with primary antibodies. 
Primary antibodies were as follows: rabbit anti-phospho-AKT (#9275S, CST and 
#9271S, CST), rabbit anti-AKT (#9272S, CST), rabbit anti-phospho-ERK (#9101S, 
CST), rabbit anti-ERK (#9102S, CST), rabbit anti-phospho-SMAD2 (#3108S, CST), 
rabbit anti-SMAD2 (#3122S, CST), rabbit anti-phospho-SMAD3 (#EP823, 
ab52903), rabbit anti-SMAD3 (#39513, CST), rabbit anti-SMAD4 (#9515S, CST), 
rabbit anti-phospho-c-MET (Tyr 1234/1235) (D26) (#3077, CST), mouse anti-c-MET 
(#3148S, CST) or goat anti-actin (#sc 1616, Santa Cruz Biotechnology, Santa Cruz, 
CA). The membranes were exposed to HRP-conjugated secondary species-specific 
antibodies (Santa Cruz Biotechnology). 
 
Spherogenicity assay 
Spherogenicity assays were performed by seeding 300 cells/well in NBM using 96-
well plates and allowing them to form spheres for a period of at least 15 days. 
Spherogenicity was assessed by counting the number of spheres. Data are 
expressed as mean ± SD. 
 
Flow cytometry 
The cells were dissociated with Accutase™ (Chemie Brunschwig, Basel, 
Switzerland). For cell cycle analysis 106 cells/condition were fixed and 
permeabilized with cold 70% ethanol. After two PBS washes, the cells were treated 
with RNase A (Gibco, Grand Island, NY) for 30 min at 4°C to remove RNA and 
ensure only DNA is stained with propidium iodide (PI) (Sigma-Aldrich). For cell death 
analysis, 105 cells were re-suspended in Annexin buffer [10 mM HEPES, 140 mM 
NaCl, 2.5 mM CaCl2, pH= 7.4] and incubated with Annexin-V-FITC (BD Biosciences, 
Franklin Lakes, NJ) and PI (Sigma-Aldrich) containing 0.1% Triton X-100 (Sigma-
Aldrich) for 15 min at room temperature in the dark. Cells were re-suspended in flow 
cytometry buffer [PBS, 0.5% BSA, 0.02% NaN3, 1 mM EDTA] and cell death and 
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cell cycle phases were analyzed by flow cytometry in a BD FACSVerseTM flow 
cytometer (Becton Dickinson AG, Allschwil, Switzerland). Data were analyzed using 
FlowJo Software, version 10.0.8 (Ashland, OR). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Supernatants of 2x106 cells were collected after 24 h and concentrated using an 
Amicon Ultra centrifugal filter (3K) (Millipore, Temecula, CA). For quantitative 
detection of secreted HGF, a HGF ELISA kit (#KAC2211, Invitrogen, Basel, 
Switzerland) was used according to the manufacturer's protocol. 
 
RNA interference 
To silence the expression of SMAD2, SMAD3, SMAD4 and ALK-5 GIC were 
transiently transfected by electroporation (Neon transfection system, Invitrogen) 
using siRNA pools (100 nM final concentration), containing four selected siRNA 
duplexes, each with a modification pattern that eliminates off-target effects (ON-
TARGET plus human SMAD2 siRNA- SMART pool L-003561-00, ON-TARGET plus 
human SMAD3 siRNA- SMART pool L-020067-00-0020, ON-TARGET plus human 
SMAD4 siRNA- SMART pool L-003902-00 and ON-TARGET plus human ALK-5 
siRNA- SMART pool L-003929-00) (Dharmacon, Lafayette, CO). Non-targeting 
siRNA pool was used as a negative control. Lentiviral pGIPZ vectors encoding c-
MET-specific (Oligo ID V3LHS_642486) or non-silencing control shRNA lentivirus 
(Oligo ID RHS4346) were purchased from Thermo Scientific (Waltham, MA). 
Lentiviral particles were produced in HEK 293T cells using pGIPZ shRNAmir 
lentiviral vector, pCMV-dR8.91 packaging and pMD2.G envelope plasmids. Glioma 
cells were transduced with lentiviral particles and stably transduced clones were 
isolated with 4 µg/ml puromycin and subjected to analyses after 1-5 passage post-
selection. Efficiency of gene silencing was assessed by RT-PCR and immunoblot. 
 
Immunocytochemistry (ICC) and immunohistochemistry (IHC) 
Single or double antigen labeling of formalin-fixed 4-μm-thick sections by ICC or IHC 
included the following steps: deparaffinization, rehydration of sections and following 
heat-induced antigen retrieval by boiling in EDTA buffer (1 mM EDTA, 0.05% Tween 
20, pH 8.0) for 15 min in a steamer, treatment with 1% H2O2 for 15 min, blocking in 
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SuperBlock solution (#AAA125, ScyTek Laboratories, Logan, UT) for 30 min at room 
temperature in a humid chamber and primary antibody incubation. The following 
primary antibodies were used: rabbit anti-phospho-c-MET (Tyr1234/1235) 
polyclonal antibody (# AF2480, R&D Systems), isotype rabbit IgG control 
(#ab27472, abcam, Cambridge, UK), mouse monoclonal anti-TGF-β2 antibody (# 
ab36495, abcam) or mouse IgG1 monoclonal (NCG01) - isotype control (# ab81032, 
abcam). Incubation with these antibodies was followed by horseradish peroxidase 
(HRP)-conjugated anti-rabbit IgG secondary antibody (#sc-2030, Santa Cruz) or the 
VECTASTAIN ABC-alkaline phosphatase (AP) detection system (containing 
biotinylated anti-mouse IgG) (#AK-5002, Vector Labratories, Burlingame, CA). The 
HRP green precipitate is ideal for double staining given its good contrast to red 
chromogenic substrates used with AP detection systems. For color development 
Permanent HRP Green (#ZUC070-100, Zytomed System, Berlin, Germany) and 
VectorRed (#SK-5100, Vector Labratories) substrate kits were used. In double stain 
procedures, VectorRed was used as the last chromogen. Specificity verification and 
titration of primary and secondary antibodies were carried out first by ICC. To 
perform reliability testing for the anti-TGF-β2 antibody, TGF-β2-negative ZH-161 
and ZH-305 cells with moderate levels of TGF-β2 expression were selected. 
Similarly, to test the anti-phospho-c-MET antibody, c-MET/p-c-MET-negative T-269 
and c-MET/p-c-MET-positive ZH-161 cells were used. The 3D-cultured GIC spheres 
were embedded into paraffin blocks without trypsinization according to a slightly 
modified protocol (Pinto, 2011). Embedded cells were sectioned and subsequently 
subjected to standard staining procedures as specified above. The evaluation of 
antigen expression in human tumors in vivo was performed on tumor nodules, which 
were demarcated from the normal brain tissue based on histomorphological features 
of glioblastoma including the presence of microvascular proliferation, prominence of 
glomeruloid vessels, nuclear atypia, high mitotic activity confirmed by KI-67 staining 
and necrosis. The immunohistochemically stained sections were viewed by a Nikon 
Eclipse 80i (Nikon Corporation, Tokyo, Japan) microscope with a Nikon CFI Plan 
Apo Lambda 40X (Nikon Corporation) bright field objective, Olympus UC30 
(Olympus K.K., Tokyo, Japan) camera and processed by cellSens Entry 1.12 by 
Olympus Corporation (Olympus K.K.) software. To compare the proportion of each 
antigen to the other in the same tumor specimen, the quantification of each 
chromogen was performed separately within three randomly selected different 
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microscopic fields of each specimen using Image J (version 1.32j) software 
(National Institutes of Health, http://rsb.info.nih.gov/ij/). To separate different 
chromogens a color deconvolution module was used. TGF-β2 and p-c-MET 
immunoreactivities were determined by measuring the integrated density (the sum 
of the pixel values) per field (tumor region). The results per tumor region were then 
pooled and averaged for each patient and for each chromogen separately. A cutoff 
of 5% stained tumor cells was used to allocate a sample to the TGF-β2 and p-c-
MET high or low groups. The staining procedure, image acquisition, threshold 
settings were identical for the entire set of patient samples. Clinical information on 
the cohort of 58 newly diagnosed and 8 recurrent glioblastoma patients used in this 
study has been published (Frei et al., 2015). 
 
Statistical analysis 
All in vitro experiments reported here were performed in biological and technical 
replicates. Results of representative experiments are shown. Quantitative data were 
expressed as the mean and SD of triplicate determinations. The statistical analyses 
were performed by student t-test and one-way ANOVA with Tukey’s multiple 
comparison tests wherever applicable (GraphPad Software, La Jolla, CA). A p value 
below 0.05 was considered significant. The Spearman’s rank correlation coefficient 
was calculated to analyze the statistical association between the mean of TGF-β2 
and p-c-MET levels (integrated density values) in vivo. 
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5. Aims of the thesis 
Therapeutic resistance in glioblastoma has been recently attributed to the complex 
network of interactions between oncogenic signaling cascades. Approaches 
targeting specific pathways lead to compensatory mechanisms initiated by other 
functionally redundant signaling, thus rendering glioblastoma refractory to therapies. 
Combinatorial strategies have gained considerable interest in reaching therapeutic 
efficacy. Among multiple pathways associated with glioblastoma, the HGF/c-MET 
and TGF-β pathways are considered drivers of resistance to irradiation and 
maintenance of the treatment-refractory GIC population. Despite the significant role 
in glioblastoma pathogenesis, their potential interactions remain uncharacterized. 
Therefore, the aims of this thesis were: 
 
 To characterize patient-derived GIC models for their basal TGF-β and HGF/c-
MET pathways activity. 
 To evaluate if genetic and pharmacological modulation of the TGF-β signaling 
pathway influences HGF/c-MET signaling activity in c-MET-positive GIC models. 
 To identify the molecular mechanisms involved in TGF-β-dependent control of 
HGF/c-MET signaling by interfering at different levels with the TGF-β pathway. 
 To study the control of glioma stem cell properties by TGF-β and HGF/c-MET 
pathways alone and by their balance in c-MET-positive versus negative GIC 
models, in order to determine the functional relevance of this molecular 
interaction.  
 To corroborate the results in vivo using human glioblastoma specimens.  
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6. Results and Discussion 
 
 
6.1 Crosstalk of the HGF/c-MET and TGF-β pathways in glioblastoma 
 
A related manuscript has been submitted 
 
Eleanna Papa1, Michael Weller1, Emese Szabo1 
 
1 Laboratory of Molecular Neuro-Oncology, Department of Neurology, University 
Hospital and University of Zurich, Zurich, Switzerland. 
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Eleanna Papa performed all the experiments of this work. Emese Szabo and 
Michael Weller guided all the experiments of this work. 
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6.1.1 Results 
Characterization of HGF/c-MET pathway and TGF-β ligands expression in GIC 
We first analyzed c-MET pathway in three different patient-derived GIC models 
referred to as ZH-161, ZH-305 and T-269. The levels of HGF and c-MET were 
assessed in all GIC lines (Fig. 12A and B). Consistent with the expression of HGF 
and c-MET mRNA (Fig. 12A) the ZH-161 and ZH-305 models exhibited basal level 
of phosphorylated thus active c-MET (p-c-MET) as demonstrated by immunoblot 
and immunocytochemistry (Fig. 12B and C). Despite comparable expression levels 
of HGF and c-MET mRNA and total c-MET protein amount in ZH-161 and ZH-305, 
c-MET phosphorylation was significantly higher in ZH-161. The expression of HGF 
and c-MET mRNA as well as c-MET protein levels were below detection limit in T-
269 (Fig. 12A and B). In line with the absence of c-MET, these cells were negative 
for p-c-MET by immunoblot and immunocytochemistry (Fig. 12B and C). Overall, 
these results allowed us to define ZH-161 and ZH-305 as c-MET-positive GIC 
models and T-269 as a c-MET-negative GIC model. 
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Figure 12. Characterization of the HGF/c-MET pathway in GIC. (A) HGF and c-MET 
mRNA levels were quantified by RT-PCR. (B) Equal amount of cellular lysates were 
assessed for c-MET and p-c-MET levels by immunoblot. Actin was used as loading 
control. (C) Paraffin-embedded spheres were sectioned and stained for p-c-MET 
(HRP) using 0.5 µg/ml primary antibody or rabbit isotype control. Nuclei were 
counter-stained with hematoxylin (blue) (scale bars: 50 μm). 
 
 
Next, the expression levels of all three TGF-β ligands (TGF-β 1/2/3) were assessed 
at mRNA level in the same GIC models. TGF-β1 and TGF-β3 expression levels 
were similar in our GIC panel. TGF-β2 was predominantly expressed by ZH-305 
(Fig. 13A). TGF-β2 mRNA correlated with TGF-β2 protein levels assessed by 
immunocytochemistry in ZH-161 and ZH-305 (Fig. 13B). 
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Figure 13. TGF-β ligands in GIC. (A) TGF-β 1/2/3 mRNA levels were quantified by RT-
PCR. (B) Paraffin-embedded spheres were sectioned and stained for TGF-β2 (AP) 
using 0.5 µg/ml primary antibody mouse isotype control. Nuclei were counter-stained 
with hematoxylin (blue) (scale bars: 50 μm). 
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TGF-β suppresses HGF/c-MET pathway activity in glioblastoma 
We next investigated the potential effects of TGF-β modulation on c-MET pathway 
activity using the ZH-161 and ZH-305 models. The exposure of the cells to 
recombinant TGF-β2 induced activation of TGF-β signaling, as defined by increased 
p-SMAD2 levels, and resulted in significant reduction of c-MET phosphorilation 
displayed by immunoblot (Fig. 14A) and immunocytochemistry (Fig. 14B). A minor 
decrease in total c-MET was observed upon TGF-β2 stimulation, too. The next step 
was to block TGF-β signaling by the use of a TGF-βRI (ALK-5) inhibitor, SD-208. 
Although SD-208 did not affect basal p-c-MET levels, it prevented the reduction of 
p-c-MET when combined with recombinant TGF-β2 (Fig. 14A). 
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Figure 14. Control of c-MET activity by TGF-β signaling. (A) GIC were seeded in 
complete NBM in the presence of SD-208 (1 µM) or TGF-β2 (2 ng/ml) or both for 24 h. 
DMSO diluted in NBM (1:20’000) served as a control. p-SMAD2, p-c-MET and c-MET 
protein levels were assessed by immunoblot. 30 µg/lane protein for ZH-161 and 50 
µg/lane for ZH-305 were loaded. Actin was used as loading control. Quantification of 
band intensity by Image J is shown below the immunoblot panels. (B) GIC were 
seeded in complete NBM in the presence of TGF-β2 (2 ng/ml) for 24 h and 
subsequently embedded in paraffin. Paraffin-embedded spheres were sectioned and 
stained for p-c-MET (HRP) using 0.5 µg/ml primary antibody rabbit isotype control. 
Nuclei were counter-stained with hematoxylin (blue) (scale bars: 50 μm). 
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The involvement of TGF-βRI in TGF-β-induced p-c-MET reduction was further 
confirmed using a second TGF-βRI inhibitor, LY2157299, in ZH-161. Similar to SD-
208, LY2157299 did not modulate basal p-c-MET but it prevented the negative effect 
of exogenous TGF-β2 on c-MET phosphorylation (Fig. 15A). To exclude potential 
off-target effects of the pharmaceutical inhibitors, we used siRNA oligonucleotides 
to specifically silence the expression of ALK-5 in ZH-161. Compared to control 
transfected cells, we achived a 85% reduction in ALK-5 expression at mRNA level. 
Moreover, to prove the role of ALK-5 mediated signaling, we assessed the 
expression of PAI-1, a recognized downstream target of TGF-β/ALK-5 cascade. We 
observed that TGF-β2-dependent up-regulation of PAI-1 was prevented in ALK-5 
siRNA-transfected cells. Consistent with the pharmacologic inhibition of ALK-5, the 
genetic blockade of this receptor was proven to be effective in countering TGF-β2 
negative control of p-c-MET levels (Fig. 15B). Overall, we demonstrated that the 
TGF-β signaling pathway exerts a negative effect on c-MET signaling in a TGF-βRI-
dependent manner. 
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Figure 15. Role of ALK-5 in the control of c-MET activity by TGF-β2. (A) ZH-161 were 
seeded in complete NBM in the presence of LY2157299 (1 µM) or TGF-β2 (2 ng/ml) or 
both for 24 h. DMSO diluted in NBM (1:20’000) served as a control. (B) Transient 
genetic depletion of ALK-5 was performed by transfecting 100 nM siRNA in ZH-161 
using Neon® Transfection System MPK5000. Where indicated, the cells were 
stimulated 24 h post-transfection with TGF-β2 (2 ng/ml) for 24 h. Control cells were 
left unstimulated. Silencing efficiency of ALK-5 (left) and expression levels of TGF-
β2 target gene PAI-1 (middle) were assessed by RT-PCR. Cells under these 
conditions were assessed for (right) p-SMAD2, p-c-MET and c-MET protein levels by 
immunoblot. 30 µg/lane protein were loaded. Actin was used as loading control.  
 
 
 
 59 
 
TGF-β2 interferes with HGF levels to prevent c-MET phosphorylation 
HGF is the only recognized ligand for c-MET receptor and its binding triggers c-MET 
phosphorylation. This prompted us to determine whether the reduction in p-c-MET 
upon exposure to TGF-β2 was parallel by a modulation of HGF levels in ZH-161 
and ZH-305. We observed that exogenous TGF-β2 significantly reduced HGF 
mRNA expression (Fig. 16A) and protein release detected by RT-PCR and by 
ELISA assays, respectively (Fig. 16B). The downregulation of HGF expression and 
secretion upon TGF-β2 was prevented by SD-208 in both cell lines (Fig. 16A and 
B).  
 
 
Figure 16. Control of HGF levels by TGF-β signaling. GIC were seeded in complete 
NBM and stimulated with TGF-β2 (2 ng/ml) for 24 h in the absence or presence of SD-
208. (A) Modulation of HGF mRNA expression was assessed by RT-PCR. (B) HGF 
protein release into the supernatant was measured by ELISA (*p < 0.05, **p < 0.01, 
effect of TGF-β2 compared to control, #p < 0.05, ##p < 0.01 effect of TGF-β2 and SD-
208 co-treatment compared to TGF-β2 alone). 
 
 
In contrast, c-MET mRNA expression was downregulated by exogenous TGF-β2 in 
ZH-305 only and it remained stable with co-treatment of TGF-β2 and SD-208 in both 
cell lines (Fig. 17).  
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Figure 17. TGF-β2-dependent control of c-MET expression. GIC were seeded in 
complete NBM in the absence or presence of SD-208 (1 µM) or TGF-β2 (2 ng/ml) or 
both for 4 h. DMSO diluted in NBM (1:20’000) served as a control. Modulation of c-
MET mRNA expression in ZH-161 (left) or ZH-305 (right) cells was analyzed by RT-
PCR (***p < 0.001, effect of TGF-β2 compared to control, ###p < 0.001 effect of TGF-β2 
and SD-208 co-treatment compared to TGF-β2 alone). 
 
 
To further prove that the negative control of HGF by TGF-β led to reduction of p-c-
MET levels, we stimulated the cells with recombinant HGF and tested whether the 
p-c-MET levels were rescued by exogenous HGF in the presence of TGF-β2. 
Indeed, HGF restored p-c-MET levels in TGF-β treated cells (Fig. 18), suggesting 
loss of HGF expression as a mechanism in the negative regulation of c-MET 
pathway by TGF-β. 
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Figure 18. TGF-β2 modulation of HGF-dependent c-MET phosphorylation. GIC were 
seeded in complete NBM and stimulated with HGF (50 ng/ml) or TGF-β2 (2 ng/ml) or 
both for 24 h. p-SMAD2, p-c-MET and c-MET protein levels were assessed by 
immunoblot; 30 µg/lane protein for ZH-161 and 50 µg/lane for ZH-305. Actin was used 
as loading control. 
 
 
TGF-β suppression of HGF/c-MET pathway occurs in a SMAD-independent 
manner 
To clarify the molecular events in the TGF-β-dependent suppression of HGF/c-MET 
pathway activity, we first analyzed the involvement of SMAD proteins, the central 
effectors of TGF-β canonical signaling. We used siRNA oligonucleotides to 
specifically silence the expression of SMAD2, SMAD3 or SMAD4 in ZH-161 and ZH-
305. Compared to control transfected cells, SMAD2, SMAD3 and SMAD4 
expression levels were significantly reduced at both mRNA (Fig. 19A) and protein 
(Fig. 19B) levels. In contrast to TGF-βRI inhibition, SMAD2, SMAD3 or SMAD4 
silencing did not counteract the TGF-β2-evoked suppression of c-MET 
phosphorylation (Fig. 19B). 
Silencing of each SMAD did not affect the protein levels of the other SMAD, which 
confirms the specificity of the siRNA constructs. Moreover, by measuring PAI-1 
expression, we further proved the efficiency of SMAD silencing in preventing TGF-
β downstream target activation. We indeed observed that exogenous TGF-β2-
dependent up-regulation of PAI-1 was lost in SMAD knockdown cells (Fig. 19C). 
These findings allowed us to exclude a role for SMAD proteins in TGF-β-dependent 
HGF/c-MET pathway inhibition. 
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Figure 19 continues on the next page. 
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Figure 19. Role of SMAD proteins in the control of the c-MET pathway by TGF-β2. 
Transient genetic depletion of SMAD2, SMAD3 or SMAD4 was performed by 
transfecting 100 nM siRNA in ZH-161 or ZH-305 using Neon® Transfection System 
MPK5000. Where indicated, the cells were stimulated 2 h post-transfection with TGF-
β2 (2 ng/ml). 24 h later, the silencing efficiency of SMAD2, SMAD3, SMAD4 was 
assessed by (A) RT-PCR and (B) by immunoblotting (30 µg/lane protein were loaded). 
Actin was used as loading control. (C) PAI-1 gene expression was assessed by RT-
PCR. Unstimulated cells were used as references.  
 
 
TGF-β suppresses HGF/c-MET pathway activity in glioblastoma via 
MAPK/ERK and AKT non-canonical signaling 
In addition to SMAD proteins, TGF-β superfamily members transmit signals via 
SMAD-independent pathways including various branches of MAPK/ERK and 
PI3K/AKT cascades. Thus, we assessed whether these pathways might mediate 
TGF-β-dependent inhibition of HGF/c-MET signaling. We first analyzed the effect of 
exogenous TGF-β2 on MAPK/ERK cascade activation by measuring the 
phosphorylated levels of the ERK 1/2 terminal kinase. Exposure to TGF-β2 induced 
ERK 1/2 phosphorylation in both ZH-161 and ZH-305. The use of U0126, a highly 
selective inhibitor that blocks the activation of ERK 1/2, interfered with both basal 
and TGF-β2-induced ERK 1/2 phosphorylation in ZH-161 and ZH-305 (Fig. 20A). 
We next explored the involvement of ERK 1/2 in TGF-β-dependent modulation of 
HGF/c-MET pathway. U0126 alone altered neither c-MET phosphorylation (Fig. 
20A) nor HGF mRNA levels (Fig. 20B), but it counteracted the inhibitory effect of 
exogenous TGF-β2 on HGF/c-MET pathway in both cell lines. Moreover, U0126 
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prevented the downregulation of c-MET mRNA expression by TGF-β2 in ZH-305 
(Fig. 20C). 
 
 
 
Figure 20. Analysis of MAPK/ERK signaling in the control by TGF-β2 of c-MET 
activity. GIC were treated with U0126 (10 µM) or TGF-β2 (2 ng/ml) alone or 
combination and assessed for: modulation of (A, upper panel) ERK phosphorylation 
(4 h) and (A, lower panels) c-MET activation (16 h) by immunoblot and of (B) HGF or 
(C) c-MET mRNA by RT-PCR (4 h) (*p < 0.05, **p < 0.01, effect of TGF-β2 compared to 
control, ωp < 0.05, effect of TGF-β2 and U0126 co-treatment compared to TGF-β2 
alone).  
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The involvement of PI3K/AKT signaling in TGF-β-dependent control of c-MET 
pathway was also adressed. Therefore, similar analyses as described above were 
carried out using AZD5363, as a tool to inhibit the phosphorylation of AKT substrate. 
The increase of p-AKT (Ser473, Thr308) in both ZH-161 and ZH-305 reflects the 
mode of action of this inhibitor (Davies et al., 2012) (Fig. 21A). Although exposure 
to TGF-β2 did not modulate p-AKT (Thr308; Ser473) and AZD5363 alone did not 
modify HGF expression, the inhibition of p-AKT by AZD5363 partially rescued both 
p-c-MET and HGF levels in TGF-β2-treated cells (Fig. 21A and B). Further, the 
downregulation of c-MET mRNA expression by TGF-β2 was blocked by AZD5363 
in ZH-305 (Fig. 21C).  
Overall, these results suggest a role for MAPK/ERK and AKT in the mechanism of 
HGF/c-MET pathway activation upon exogenous TGF-β in c-MET positive GIC 
models. 
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Figure 21. Analysis of the effects of AKT signaling for the control of TGF-β2-
dependent modulation of c-MET activity. GIC were treated with AZD5363 (3 µM) or 
TGF-β2 (2 ng/ml) alone or combination and assessed for: (A) modulation of c-MET 
activation (16 h) by immunoblot and (B) HGF or (C) c-MET mRNA by RT-PCR (4 h) 
upon the treatments. (*p < 0.05, **p < 0.01, ***p < 0.001 effect of TGF-β2 relative to 
control; ωp < 0.05, effect of TGF-β2 and AZD5363 co-treatment relative to TGF-β2; ϴϴp 
< 0.01, effect of AZD5363 relative to control). 
 
 
 
 
 
 67 
 
Context-dependent role of HGF/c-MET and TGF-β signaling in stemness 
We next sought to investigate the functional relevance of the interactions observed 
between the TGF-β and c-MET pathways. It has been shown that aberrant activation 
of these two cascades contributes to the maintenance of stem-like features of GIC. 
This function is exerted by their control of the expression of stem-like factors, 
essential for pluripotency, such as OCT-4, SOX-2 and NANOG. Thus, we first 
evaluated how these two pathways alone and their balance influence the expression 
of stem-like markers. We stimulated or inhibited TGF-β signaling by exposure of the 
cells to recombinant TGF-β or SD-208, alone or in combination. In addition, we 
treated the cells with EMD1214063, an ATP-competitive inhibitor preventing the 
activation of c-MET. The inhibition of TGF-β signaling by SD-208 did not affect OCT-
4, SOX-2 or NANOG mRNA expression. TGF-β2 stimulation resulted in an 
approximately 2-fold decrease of these stem cell markers at mRNA expression 
levels in c-MET-positive ZH-161 and ZH-305 cells, except of OCT-4 in ZH-305. This 
reduction was prevented when GIC were exposed to recombinant TGF-β2 in 
combination with SD-208. Similar to exogenous TGF-β2, inhibition of c-MET by 
EMD1214063 resulted in transcriptional repression of the stem-like markers (Fig. 
22A and B). In contrast, none of these markers were affected by TGF-β2 or 
EMD1214063 in c-MET-negative T-269 cells (Fig. 22C).  
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Figure 22. Regulation of stem cell marker expression by TGF-β or c-MET modulation. 
OCT-4, SOX-2 or NANOG gene expression in (A) ZH-161, (B) ZH-305, (C) T-269 upon 
exposure to TGF-β2 (2 ng/ml), SD-208 (1 µM), or both (4 h) were assessed by RT-PCR 
(*p < 0.05, ***p < 0.001, effect of TGF-β2 relative to control; #p < 0.05, ###p < 0.001 effect 
of TGF-β2 and SD-208 relative to TGF-β2). The c-MET inhibitor EMD1214063 (200 nM) 
was included as a reference (ωp < 0.05, ωωp < 0.01). 
 
 
The expression of stem-like markers was described to correlate with the ability of 
GIC to grow as neurospheres and to self-renew. Therefore, the second step was to 
characterize if the reduction of the stem-like marker expression by TGF-β2 as well 
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as by blockade of c-MET pathway influence GIC spherogenicity. We cultured the 
GIC models in the presence of TGF-β2 or SD-208, or both, HGF, EMD1214063 or 
we stably silenced c-MET expression by lentiviral construct (c-MET shRNA) and 
then analyzed the effect on self-renewal of these cells. Consistent with the 
downregulation of stem-like marker expression, the exposure to recombinant TGF-
β2 of c-MET-positive GIC decreased spherogenicity in a SD-208-sensitive manner. 
Similarly, lentivirus-mediated c-MET gene silencing or c-MET inhibition with 
EMD1214063 reduced sphere formation in ZH-161 and ZH-305 GIC models (Fig. 
23A and B). Conversely, none of these treatments affected the capability to form 
spheres in c-MET negative T-269 (Fig. 23C). The efficiency of c-MET silencing was 
proven by a significant reduction of total and phosphorylated c-MET levels in ZH-
161 and ZH-305 models by immunoblot (Fig. 23D). 
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Figure 23 continues on the next page. 
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Figure 23. Effect on spherogenicity of TGF-β or c-MET modulation. (A) ZH-161, (B) 
ZH-305 or (C) T-269 cells were plated at 300 cells/well in NBM in the absence or 
presence of SD-208 (1 µM) or TGF-β2 (10 ng/ml) or SD-208 combined with TGF-β2 in 
96-well plates. ZH-161 or ZH-305 cells were either expressing c-MET shRNA or treated 
with EMD1214063. Spherogenicity was determined by counting spheres. Sphere 
formation was assessed at day 21 in triplicates (*p < 0.05, effects of TGF-β2 compared 
to control, #p < 0.05, effect of TGF-β2 and SD-208 co-treatment compared to TGF-β2 
alone; ωp < 0.05, effect of EMD1214063 compared to control, θp < 0.05, effect of c-MET 
shRNA compared to control). (D) Verification of the specificity of the 145 kDa bands 
and efficacy of c-MET gene silencing in c-MET positive GIC by immunoblot for c-MET 
and p-c-MET. 30μg/lane protein were loaded. Actin was assessed as reference.  
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Either the activation of TGF-β signaling or the inhibition of the c-MET pathway led 
to reduction in the stem-like properties of c-MET positive GIC. To evaluate whether 
the TGF-β2 effect on stemness was due to its negative control of HGF/c-MET, we 
analyzed the spherogenicity upon TGF-β2 exposures in the presence of 
recombinant HGF. GIC were cultured in medium lacking EGF/FGF and further 
stimulated with recombinant HGF. GIC cultured without EGF/FGF showed a 
tendency to attach to the plastic surface of a culture dish. The exposure to 
recombinant HGF significantly enhanced the neurosphere forming capability of both 
ZH-161 and ZH-305 but not of T-269. Additionally, the stimulation with HGF 
overcame the reduction in sphere formation observed upon TGF-β2 exposure in 
ZH-161 and ZH-305 (Fig. 24). Overall, our finding suggested that TGF-β negatively 
regulates the stem-like properties by negatively controlling HGF/c-MET activation in 
GIC models where this pathway is a master regulator of stemness. 
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Figure 24 continues on the next page. 
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Figure 24. Spherogenicity-promoting role of exogenous HGF. (A) ZH-161, (B) ZH-305 
or (C) T-269 cells were seeded at a density of 500 cells/well and grown for 21 days in 
HGF-containing (50 ng/ml) NBM with (upper panels) or without (lower panels) 
EGF/FGF. Stimulatory effects of HGF in the absence or presence of TGF-β2 (2 ng/ml) 
under these conditions were analyzed. Spherogenicity was determined by counting 
spheres. Sphere formation was assessed at day 21 in triplicates (θp < 0.05, effect of 
HGF relative to control; *p < 0.05, effect of TGF-β2 relative to control; ᶲ< 0.05, effect of 
HGF and TGF-β2 co-treatment relative to TGF-β2).  
 
 
Moreover, we found that the inhibitory effects of TGF-β2 and EMD1214063 on 
spherogenicity in ZH-161 and ZH-305 might also involve minor cytotoxicity as 
demonstrated by changes in viability (Fig. 25A) and cell cycle progression (Fig. 25B) 
under these conditions. 
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Figure 25 continues on the next page. 
 
 76 
 
 
 
 
Figure 25 continues on the next page. 
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Figure 25. Effect of TGF-β treatment and c-MET inhibition on viability and cell cycle 
progression. ZH-161, ZH-305 and T-269 were exposed to TGF-β2 (2 ng/ml) or 
EMD1214063 (1 µM) for 72 h. DMSO diluted in NB medium (1:20’000) served as a 
control. (A) Induction of cell death was evaluated by annexin V (AnnV)/PI staining. 
(B) Cell cycle phase distribution profiles were obtained by PI staining using flow 
cytometry. Cell fractions are shown for non-treated versus treated cells in 
histograms as well as bar graphs. 
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Detection and significance of intratumoral TGF-β and HGF/c-MET 
heterogeneity in glioblastoma  
 
The findings of an inhibitory effect on HGF/c-MET by TGF-β in vitro prompted us to 
validate an association between TGF-β and c-MET pathways in vivo using human 
glioblastoma specimens. The specificity of the antibodies and the optimal conditions 
for immunohistochemistry were determined as previously described using paraffin-
embedded positive and negative control cell lines (Fig. 13 and 14). TGF-β2 mRNA-
expressing ZH-305 cells were immunopositive whereas TGF-β2 mRNA-negative 
ZH-161 cells were also negative by immunocytochemistry. Similar studies were 
performed to test the anti-p-c-MET antibody in ZH-161 and T-269 cells by 
immunoblot and immunohistochemistry. We co-stained glioblastoma tissue samples 
from a large cohort of 66 different glioblastoma patient for TGF-β2 (red) and p-c-
MET (green). p-c-MET was detected in glioblastoma cells as well as in the 
vasculature (Fig. 26A). p-c-MET immunoreactivity was observed mainly in the 
membrane and less in the cytoplasm. TGF-β2 was localized intracellularly as well 
as in the extracellular space, showing a diffuse staining pattern (Fig. 26B and C). 
Double staining of TGF-β2 and p-c-MET allowed the classification of the tumor 
specimens into four groups (Fig. 26D). In line with our in vitro findings of a negative 
control by TGF-β of c-MET activation, the two antigens were rarely present 
simultaneously in the same tumor specimen (n=13). Moreover, co-expression of 
TGF-β2 and p-c-MET in the same tumor cells was rarely detected (Fig. 26C, see 
arrowhead), showing that these two antigens exhibit almost mutually exclusive 
staining patterns among patients and within the tumor from the same patient. 
Accordingly, a negative correlation was detected between TGF-β2 and p-c-MET 
(r=−0.29, p=0.02). 
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Figure 26. Simultaneous detection of TGF-β2 and phosphorylated c-MET in 
glioblastoma. Double immunostaining was performed on formalin-fixed, paraffin-
embedded surgical glioblastoma specimens. (A-C) Representative images show 
hematoxylin and eosin (H&E) staining (upper panels); p-c-MET immunoreactivity in 
green (A and C, middle and lower panels) and TGF-β2 in red (B and C, middle and 
lower panels) in tumor regions of three patients. Nuclei are counter-stained with 
hematoxylin (blue). The scale bars correspond to 50 μm. (D) Graphical representation 
of the percentage of glioblastomas high for either TGF-β2 or p-c-MET or both. 
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Thus, we revealed a novel molecular and functional aspects of TGF-β - HGF/c-MET 
signal interaction shedding some light on a complex regulation of cancer cell self-
renewal in glioblastoma (Fig. 27). 
 
 
 
Figure 27. Overview of the crosstalk between HGF/c-MET and TGF-β pathways in 
glioblastoma. TGF-β inhibits c-MET activity through phosphorylation of MAPK/ERK 
kinase. The PI3K/AKT pathway is also involved in the regulatory mechanisms of c-
MET activity by TGF-β in patient-derived GIC models. TGF-β inhibits stemness in GIC 
at least in part via its negative regulation of c-MET activity.  
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6.1.2 Discussion 
Glioblastoma is a universally fatal type of cancer characterized by molecular 
diversity and intratumoral heterogeneity (Patel et al., 2014). Potentially as a 
consequence of the functionally redundant cell signaling networks and multiple 
genetic alterations (Zheng et al., 2012), glioblastoma remains largely refractory to 
current approaches of cancer therapy targeting specific signaling pathways (Prados 
et al., 2015). Given their role in mediating migration and invasiveness, resistance to 
irradiation and maintenance of the glioma stem cell pool, both HGF/c-MET and TGF-
β signaling pathways are considered as potential therapeutic targets. Several 
approaches evaluated the inhibition of TGF-β signaling in glioma 
(www.clinicaltrials.gov) using antibodies, antisense oligonucleotides, ligand traps or 
TGF-β receptor kinase inhibitors (Han et al., 2015). Similarly, many clinical trials 
explored a therapeutic role for HGF/c-MET inhibition. None of these approaches 
have been successful in the clinic (Awad et al., 2014; Cloughesy et al., 2017). 
Association between the TGF-β and HGF/c-MET signaling pathways has been 
demonstrated in other cancer types. The TGF-β pathway in fibroblasts suppresses 
mammary tumorigenesis by antagonizing HGF/c-MET signaling to promote 
scattering and invasion (Cheng et al., 2007; Cheng et al., 2008). Moreover, TGF-β 
negatively regulates c-MET and HGF mRNA levels by SMAD2-mediated 
transcriptional repression in human squamous carcinoma cells (Hoot et al., 2013). 
In astrocytoma cells, TGF-β family ligands decrease HGF synthesis and secretion 
(Chattopadhyay et al., 2004). However, the functional interactions between TGF-β 
family members and HGF/c-MET signaling in glioblastoma pathogenesis remained 
uncharacterized. 
Here we have elucidated the crosstalk between the TGF-β and HGF/c-MET 
dependent signaling pathways in gliobastoma using three patient-derived GIC 
models as well as human glioblastoma specimens. We selected two models with 
constitutive c-MET activation, ZH-161 and ZH-305, and included a c-MET-negative 
model, T-269, as a reference (Fig. 12). We found that TGF-β stimulation reduced c-
MET phosphorylation in ZH-161 and ZH-305 cells (Fig. 14). This was explained by 
a reduction of HGF mRNA expression and protein release (Fig 16). Exogenous HGF 
rescued c-MET pathway activity in the presence of TGF-β (Fig. 18). Additionally, 
repression of p-c-MET was associated with minor reduction of total c-MET in ZH-
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305 cells. The effect of TGF-β on HGF/c-MET pathway activation was prevented 
upon pharmacological or genetic inhibition of ALK-5 (Fig. 14-15). Silencing of 
SMAD2/3/4 gene expression did not interfere with the TGF-β-dependent control of 
the c-MET pathway. Conversely, both the blockade of the MAPK/ERK cascade by 
U0126 and of the PI3K/AKT signaling by AZD5363 attenuated the effect of TGF-β 
on c-MET phosphorylation as well as HGF gene expression (Fig. 20 and 21), 
suggesting that TGF-β activity on HGF/c-MET is regulated by both pathways. TGF-
β directly phosphorylated ERK 1/2 (Fig. 20), thus defining this non-canonical 
signaling as the major mediator of the crosstalk between TGF-β and c-MET. In 
response to exogenous TGF-β, there was only minor or no stimulation of p-AKT 
(Fig. 21), indicating a lack of direct TGF-β-PI3K/AKT interaction in these GIC lines. 
Interestingly, induction of c-MET phosphorylation was observed upon the blockade 
of PI3K/AKT signaling or - to a lesser extent - upon MAPK/ERK inhibition alone, 
confirming a negative control of c-MET activity by AKT and MAPK/ERK, warranting 
clinical investigation to determine the significance of p-c-MET as an escape 
mechanism to AKT or MAPK/ERK inhibitors (Fig. 20 and 21).  
The PI3K/AKT and ERK signaling cascades are activated in response to c-MET and 
are common downstream effectors of many receptor tyrosine kinases (Paumelle et 
al., 2002; Organ and Tsao, 2011). Some evidence supports that PI3K/AKT and ERK 
act downstream of TGF-β, too (Zhang, 2009; Akhurst and Hata, 2012).  
The low TGF-β pathway activity in these GIC models is reflected by undetectable 
phospho-SMAD2/SMAD3 by immunoblotting, furthermore by the unaltereted gene 
expression of the major effector and downstream target of TGF-β, PAI-1, upon ALK-
5 or SMAD2/3/4 gene silencing (Fig. 15 and 19). Thus, reduced TGF-β can shift the 
balance in favor of c-MET receptor activation in these GIC lines. Notably, PAI-1 
transcriptional regulation is known to be stimulated by a variety of cytokines, 
including EGF (Kasza et al., 2001; Paugh et al., 2008) independenly of TGF-β, 
which can explain the relative high basal PAI-1 mRNA levels in these cells. 
In addition, the TGF-β and c-MET signaling pathways have been associated with 
the induction of stem marker factors essential for GIC maintenance (Ikushima et al., 
2009; Penuelas et al., 2009; Anido et al., 2010; Li et al., 2011; Rath et al., 2013). 
OCT4, NANOG and SOX-2 contribute to the hallmark characteristics of stem and 
putative cancer stem cells by activation of target genes that encode pluripotency 
and self-renewal mechanisms (Wang et al., 2013). We observed that exposure to 
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TGF-β downregulated stem cell markers gene expression in c-MET-positive ZH-161 
and ZH-305, but not in c-MET-negative T-269 cells (Fig. 22). This was paralleled by 
an according suppression of spherogenicity and minor changes in viability and cell 
cycle progression (Fig. 23 and 25). c-MET inhibition had the same effects as TGF-
β stimulation in these assays. Conversely, T-269 did not respond to any 
manipulation of the TGF-β or c-MET pathways, showing a paradigm of how stem 
cell behavior is differentially regulated in different cellular contexts. As previously 
described (Moriyama et al., 1996; Lamszus et al., 1999; Walter et al., 2002; Li et al., 
2011), we induced sphere formation by stimulation of c-MET-positive GIC models 
with HGF only in the absence of EGF and FGF supplementation. Additionally, under 
these culture conditions, the stimulation with HGF overcame the reduction in sphere 
formation observed upon exposure to TGF-β2 in ZH-161 and ZH-305 (Fig. 24). 
These findings may suggest that TGF-β suppresses stem cell characteristics by 
preventing c-MET overactivation in molecular sub-types of gliomas (Fig. 27). 
Taken together, our observations allow predicting that human glioblastomas would 
tend to up-regulate either of both pathways but not both signaling simultaneously. 
This assumption was confirmed by a negative correlation between TGF-β2 and p-
c-MET immunoreactivity upon double immunostaining in a large cohort of 
glioblastoma patients (Fig. 26). In fact, the modulation of c-MET pathway activity by 
TGF-β allows to speculate that subsets of patients with glioblastoma would have 
responded to TGF-β inhibitors such as galunisertib (LY2157299 monohydrate) with 
an increase of c-MET activity which might have counteracted any potential benefit 
from TGF-β pathway inhibition (Brandes et al., 2016). Accordingly, c-MET negativity 
could be explored as a predictive biomarker for future clinical trials exploring TGF-
β inhibition in glioblastoma. 
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